Predictive risk model for radiation-induced pneumonitis in patients diagnosed with advanced esophageal cancer receiving radiation therapy alone or in combination with immunotherapy: A retrospective study

Predictive risk model for radiation-induced pneumonitis in patients diagnosed with advanced esophageal cancer receiving radiation therapy alone or in combination with immunotherapy: A retrospective study | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Predictive risk model for radiation-induced pneumonitis in patients diagnosed with advanced esophageal cancer receiving radiation therapy alone or in combination with immunotherapy: A retrospective study Wanxi Qu, Xin Wen, Rui Duan, Wadih Issa, Xiuyu Ren, Zhen Ren, and 2 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4345357/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background Radiation therapy (RT) is an essential treatment for esophageal cancer with radiation induced pneumonitis (RP) as a possible adverse event. With the emergence of immunotherapy for patients with esophageal cancer (EC), whether in combination with RT or alone it increases RP incidence, which leads to the need of reevaluating the RP risk predication paraments. Methods Clinical and physical parameters were collected from patients with clinicopathologically confirmed unresectable locally advanced EC from 1/2020 and 7/2023. The endpoint was Grade ≥ 2 RP occurrence within 6 months after radiotherapy. The χ 2 test and Logistic regression analysis were used to analyze the relationship of categorical and continuous variables with RP occurrence respectively. Multivariate Cox analysis was used to construct a RP risk model by R software, the accuracy of which was further evaluated by ROC and risk curves. Results After strict screening, 92 patients receiving RT alone and 84 patients receiving RT + Immunotherapy were eligible for inclusion in this study. The incidence of grade ≥ 2 RP in patients with EC who received RT and immunotherapy was 30.95%, which is higher compared to those who received RT alone (17.39%). Several factors were included for the construction of RP Risk Model by multivariate Cox regression in group RT and RT-I seperatly. Four factors were used for RP prediction risk model in patients who received the RT alone, and five factors were used for RP prediction risk model in patients who received the RT + Immunotherapy. The ROC curve indicated the satisfactory accuracy with AUC value was 0.734 and 0.805 in group RT and RT-I respectively. Risk curves confirmed favorable accuracy that the higher risk score, the higher RP risk, the lower interval times when RP happens after RT. Conclusions (1) The immunotherapy may increase the risk of RP. (2) We screened out five indicators (age, total irradiation dose, irradiation segmentation frequency, V15 and V20) for predicting RP incidence in EC patients receiving RT and immunotherapy combination, which provided an important theoretical basis for the RT treatment plan. esophageal cancer predictive model radiation pneumonitis immunotherapy Figures Figure 1 Figure 2 Figure 3 1. Introduction According to the GLOBOCAN 2020 estimates, esophageal cancer (EC) ranks seventh in terms of incidence and sixth in mortality overall [ 1 ] . Radiation therapy (RT) plays a vital role in the management of EC especially in unresectable locally advanced disease. Radiation induced pneumonitis (RP), is one of the most common related adverse event in patients with EC due to the anatomical proximity to the lungs [ 2 ] , [ 3 ] . In recent years, immunotherapy either alone or in combination with RT has become widely applied to patients with EC [ 4 – 6 ] . With the extensive use of RT and immunotherapy in these patients, and the well-established induced pneumonitis caused by each treatment alone, a new question concerning the incidence of RP in patients receiving the combination of RT and immunotherapy arises. Some reports suggested that the incidence of RP increased with the combination [ 7 – 9 ] , while other noted no significant difference. Moreover, several parameters were established to be predictors of RP, including V5, V10, V20 and mean lung dose (MLD) [ 10 – 12 ] . However, these parameters did not taken immunotherapy into consideration. In this study, we evaluated the incidence of RP in patients with EC who received RT alone compared to patients who received the combination of RT and immunotherapy, and we constructed a model to predict the accuracy of RP in EC patients who received the combination of immunotherapy and RT, using clinical parameters known to be associated with RP, which could provide an effective tool for individualized risk assessment of symptomatic RP (Fig. 1 ). 2. Materials and methods 2.1. Data extraction and inclusion criterias This retrospective study was conducted at the Affiliated of Xuzhou Medical University. Patients diagnosed with EC and receiving RT alone or in combination with immunotherapy between 1/2020 and 7/2023 were included. Inclusion criterias were: patients older than 18 years old, a confirmed pathology report of esophageal squamous carcinoma, to have received both immunotherapy, completion of thoracic radiotherapy and to have at least one baseline and at least one follow-up chest CT scan after RT. Exclusion criterias included active coexisting cancer, chronic lung infection before radiotherapy initiation and developing after 180 days of starting RT. Patients with incomplete or missing data were excluded. Clinical data including, baseline characteristics, comorbidities, tumor pathological and radiographical characteristics, treatment summary and dose and volume histogram (DVH) factors (GTV (gross tumor volume), PTV (planning target volume), MLD, V5/10/15/20/25/30), were extracted from electronic medical records. Vx was defined as the percentage of lung volume receiving ≥ x Gy. The following dosimetric parameters were generated based on the DVH of the lung-PTV, including the total dose of radiotherapy, GTVp, PTV, MLD and bilateral lungs V5/10/15/20/25/30. All DVH parameters were extracted and calculated from the planned dose distribution according to the Treatment Planning System. 2.2. Treatment All patients received fixed-field intensity modulated radiotherapy (IMRT). The delineation of the target area was based on upper gastrointestinal radiography, CT findings and (or) positron emission tomography-computed tomography. In our study, GTVp was defined as the primary esophageal mass volume based on imaging studies. The CTV was defined as 3.0 cm outward in the up and down direction of GTVp and 0.5–0.6 cm outward in the anterior-posterior and left-right directions plus the lymph node area where the metastatic lymph nodes were located. The PTV was defined as the CTV plus 0.5–0.8 cm margins to account for mechanical instability, esophageal tumor movement and respiratory motion. The prescribed doses were 50 to 64.4 Gy at 1.8 to 2.0 Gy per fraction once daily and 5 fractions per week. The boundaries of organs at risk were refered to the Radiotherapy and Oncology Group guidelines. All EC patients were treated with programmed death-1 (PD-1)/ programmed death ligand 1 (PD-L1) inhibitors including camrelizumab, atezolizumab, pembrolizumab, toripalimab, tislelizumab, and sintilimab. All the doses and adjustments to the immunotherapy regimen followed the National Comprehensive Cancer Network (NCCN) guidelines. 2.4 Assessments of RP The diagnosis of RP was confirmed by clinical symptoms and abnormal lung CT images based on the history of RT in the past 6 months, which cannot be attributed to infection, checkpoint inhibitor-related pneumonitis (CIP) or other diseases. Clinical symptoms includes worsening dyspnea, an associated nonproductive cough, low-grade fevers, mild chest pain, malaise and weight loss [ 3 ] and abnormal lung CT images are visualized with diffuse lung abnormalities or fibrosis limited or most to the radiation field of the lung. The severity of RP was assessed by National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 [ 12 , 13 ] . The endpoint was the presence of grade ≥ 2 RP occurring within 6 months (180 days) after RT. 2.5 Models construction 25 clinical parameters (age, smoke, gender, pathological type, location, immunotherapy drug, immunotherapy drug type, immunotherapy cycles, sequence, cTNM, T stage, N stage, M stage, total irradiation dose, irradiation segmentation dose, irradiation segmentation frequency, GTVp, PTV, MLD, V5, V10, V15, V20, V25, V30) were included for construction of RP Risk Model by multivariate Cox regression with R (V.4.3.3) vision. Risk scores were calculated by the following formulation: Risk score= \({\sum }_{1}^{\text{n}}\text{c}\text{o}\text{e}\text{f}\times {\text{f}\text{a}\text{c}\text{t}\text{o}\text{r}}_{\text{n}}\) , where coef means the coefficient value, factor means clinical paraments used for model construction and n means the number of modeling clinical paraments. ROC curve (AUC value) and risk curves were visualized by “survival ROC” package for evaluating the accuracy of RP risk model. AUC value more than 0.7 confirms the satisfied accuracy. All EC patients were classified into two cohorts according to their risk score and the cut value was the media risk scores. The relationship of risk score and clinical parameters was analyzed by cox regression analysis with “bees warm” package. 2.6 Statistical analysis Data analysis was conducted using the Statistical Package for Social Sciences (SPSS, version 29.0). The χ 2 test and Logistic regression analysis were used to analyze the relationship of categorical variables and continuous variables with RP occurrence respectively. P -values < 0.05 were considered statistically significant. 3. Results 3.1. Patient characteristics From 5/2020 to 7/2023, a total of 225 patients diagnosed with EC were identified. 115 patients received RT alone (RT group) and 110 EC patients received of RT + immunotherapy (RT-I group). Of the 115 EC patients having received RT alone, 17 cases undergone surgery, 5 cases were lost to follow-up and 1 case received incomplete RT, were excluded. Of the 110 EC patients having received RT + Immunotherapy, 12 undergone surgery, 6 cases were diagnosed with RP after 180 days, 3 cases received incomplete RT and 5 cases were lost to follow-up were excluded. In summary, only 92 patients receiving RT alone and 84 patients receiving RT + Immunotherapy were eligible for inclusion in this study. The characteristics of the eligible patients were summarized in Table 1 & Table 2 . There are 59 males (64.13%) and 33 females (35.87%) with the median age of 70.9 years (range 49–79) in group RT, while 57 males (67.86%) and 27 females (32.14%), with the median age of 69.8 (range, 48–86) years in group RT-I. In general, a larger proportion of EC patients is male (64.13% and 67.86% in group RT and RT-I respectively), with no smoking history (80.43% and 80.95% in group RT and RT-I respectively), located in the middle thoracic (57.61% and 54.76% in group RT and RT-I respectively. All patients received chemotherapy in both groups. Most patients who received immunotherapy were treated with PD-1 inhibitors (95.24%), such as camrelizumab, pembrolizumab, toripalimab, tislelizumab and sintilimab. 50.59% of patients in the RT-I group received concurrent treatment, which is defined as receiving immunotherapy within 30 days of starting RT, and 37.65% of patients received RT prior to immunotherapy. 3.2 RP incidence A total of 16 patients (17.39%) who received RT alone and 26 patients (30.95%) who received RT + Immunotherapy and fited the inclusion criteria cited in the method part had a RP. A significant difference between the two groups existed ( P = 0.035), suggesting that immunotherapy may increase the risk of RP. Moreover, all patients who received RT alone had a grade 2 RP with the median interval time of 87 days (range, 41–151 days) while 26 RP patients in group RT-I were consisting of 23 cases of grade 2 (88.5%), 1 cases of grade 3 (3.8%) and 2 cases of grade 4 (7.7%) with the median interval time of 106 days (range, 34–171 days). Further analysis showed that clinical characteristics such as age, the total irradiation dose, irradiation segmentation frequency and V15 were in positively correlated with the risk of RP occurrence in group RT-I ( P = 0.017, P = 0.020, P = 0.012, P = 0.039 respectively) (Table 2 & Table 3 B). However, no clinical features have been shown to be significantly associated with RP (Table 1 & Table 3 A) in group RT. 3.3. Construction of RP Risk Model in EC patients Several factors were included for the construction of RP Risk Model by multivariate Cox regression in group RT and RT-I seperatly. Four factors were used for RP prediction risk model in patients who received the RT alone, including age, N, M and V20 with the following formula: Risk score = (-0.0594×age) +(0.6899×N stage) + (-1.8524×M stage) + (0.1205×V20) (Table 4 A and Fig. 2 A). Meanwhile, five factors were used for RP prediction risk model in patients who received the RT + Immunotherapy (group RT-I): age, total irradiation dose, irradiation segmentation frequency, V15 and V20. The formula was: Risk score = (-0.0555×age) + (0.1291×total irradiation dose) + (-0.2190×irradiation segmentation frequency) + ( -0.2134×V15) + (0.2214×V20) (Table 4 B, Fig. 3 A). N and M stage were assigned as categorical variable while age, total irradiation dose, irradiation segmentation frequency, V15 and V20 were assigned as numerical variable. The ROC curve indicated the satisfactory accuracy with AUC value was 0.734 and 0.805 in group RT and RT-I respectively (Fig. 2 B & Fig. 3 B). Furthermore, Risk curves confirmed favorable accuracy that the higher risk score, the higher RP risk, the lower interval times when RP happens after RT (Fig. 2 C & Fig. 3 C). We further analyzed the clinical correlation of risk score in EC patients by univariable analysis. Figure showed that risk score was highly interdependent with immunotherapy drug ( P = 0.000017 respectively) (Fig. 3 D). 4. Discussion Tumor-cell PD-L1 is expressed in 50% of patients with advanced EC [ 14 , 15 ] . While the major clinical benefits reported from the use of PD-1/PD-L1 inhibitors [ 16 , 17 ] , the accompanying risk of adverse events cannot be underestimated [ 18 ] . RP is a common adverse event occurring in 10–30% of patients with chest malignancies treated with RT [ 2 , 19 ] . Many clinical factors such as age, smoking history, the size of tumor, MLD, V20 and the lung volume receiving low-dose irradiation are known to be independent risk factor for the occurence of RP [ 20 – 25 ] . However, the introduction of immunotherapy to the standard of care in this population should lead to the re-assessment of this pattern. In our study, the incidence of grade ≥ 2 RP in patients with EC who received RT and immunotherapy was 30.95%, which is higher compared to those who received RT alone (17.39%). Most RP occurred 106 days after RT, which was consistent with previous studies [ 26 , 27 ] , however patient who received RT alone developed a delayed RP compared to those in the RT-I group (87 days). Age, the total irradiation dose, irradiation segmentation frequency and V15 are independent predictive factors for the development of grade ≥ 2 RP in patients with unresectable locally advanced EC receiving RT + Immunotherapy. Age was shown to be negatively associated with the development of RP in patients with EC in our study, which is comparable to patients with lung cancer who received chest irradiation [ 28 ] . Younger age group may possess a stronger immune response than older patients, which account for the higher risk of RP. Cytokines such as tumor necrosis factor alpha (TNF-α), transforming growth factor beta (TGF-β), interleukin (IL)-1, IL-6 as well as reactive oxygen and growth factors released from irradiated lung cells further recruit inflammatory cells to alveoli, which could lead to the development of an acute-phase pneumonitis [ 29 – 31 ] . Interestingly, although a non-smoking status showed a trend to be protective from the development of RP, the statistical analysis was not significant, which may be accountable to the small cohort size. Besides, RP is associate with a radiation therapy in a dose dependent manner, which was consistent with our analysis showing that higher total irradiation doses are associated with a higher risk of RP [ 32 ] . The NCCN guidelines (Version 1.2023) recommend that the lung dose limits for EC patients are as follows: V5 ≤ 50%, V10 ≤ 40%, V20 ≤ 20%, V30 ≤ 15%, and V40 ≤ 10%. V5, V20, V30, and MLD have been identified as independent predictors of RP [ 33 – 35 ] . In our study, V15 was found to be related with RP occurrence, which was reported in the literature in predicting the development of grade ≥ 2 RP [ 36 ] . V15 may be an important factor to consider when discussing the benefits and adverse events that may occur after receiving RT + Immunotherapy. In order to construct an optimistic RP prediction risk model, all clinical parameters were included in R vision for cyclic modeling inspection. Ultimately, four and five parameters were screen out in two groups. Several studies tried to establish a risk model including only one parameter: V20. Current studies showed that V20 > 20% was a risk factor for RP [ 37 – 39 ] , however we found that 69% of RP cases occurred with a V20 ≤ 20% in patients receiving RT alone. Our risk model combines several factor to predict the risk of RP however larger cohort are required to reevaluate the predictive value of a V20>20% when combined with other factors age and N, M stage. In EC patients who received RT + immunotherapy, more paraments should be included for RP risk prediction. Except for four parameters which are significantly related to RP occurrence (age, total irradiation dose, irradiation segmentation frequency and V15), V20 was also included in RP prediction risk model. According to the coefficient value, the smaller number of irradiation segmentation frequency, the higher total irradiation dose, the higher incidence of RP. It is easy to be explained that lung tissue belongs to late responding tissue, which is more sensitive to single dose. In summary, age and V20 are very important parameters for predicting RP risk. Whether EC patients received immunotherapy or not, age and V20 were typical factors to be evaluate while establishing the treatment plan and calculating the RP incidence risk. In the era of immunotherapy, age, total RT dose, irradiation segmentation frequency, V15 and V20 should be reevaluated. Nevertheless, our study encountered several limitations. Including the retrospective design and the fact that all the patients received chemotherapy. Therefore, no comparison of differences in various chemotherapy regimens were available. In addition, the majority of patients included in this study were diagnosed with squamous carcinomas, which are more common in China, compared to adenocarcinomas, which are more prevalent in Europe and the United States. Therefore, the probability of RP and the risk factors for adenocarcinoma of the esophagus in the real world needs to be further explored. 5. Conclusions With the increasing use of immunotherapy in combination with radiation therapy in patients with advanced EC, we showed an increased incidence of RP in patients receiving RT + Immunotherapy compared to patients who received RT alone. We further analyzed clinical parameters associated with RP and constructed a RP prediction risk model consisting of five parameters in EC patients, which may provide a basis for revising lung dose constraints in efforts to better prevent RP. Larger cohorts and prospective studies are required to establish and validate a new definitive model risk for patients with EC receiving the combination of RT + Immotherapy which could enable better treatment planning for this population List Of Abbreviations RT (radiation therapy)；RP (radiation induced pneumonitis)； EC (esophageal cancer); MLD (mean lung dose); GTV (gross tumor volume); PTV (planning target volume); DVH (dose and volume histogram); IMRT (intensity modulated radiotherapy); PD-1 (programmed death-1); PD-L1 (programmed death ligand 1); CIP (checkpoint inhibitor-related pneumonitis); TNF-α (transforming growth factor alpha); TGF-β(transforming growth factor beta); IL (interleukin); CTCAE (Common Terminology Criteria for Adverse Events); NCCN (National Comprehensive Cancer Network) Declarations Ethics approval and consent to participate This study was approved by the affiliated hospital of Xuzhou medical university research ethics board (XYFY2020-YL009). Consent for publication Not applicable. Avaliability of date and materials The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. Competing interests The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Funding This work was supported by Xuzhou special fund in scientific and technological innovation promotion (KC23266) and the Introduction of Specialist Team in Clinical Medicine of Xuzhou (2019TD003). Athors’ contributions All authors contributed to the study conception and design. Study design: Xin Ding, Longzhen Zhang and Wanxi Qu. Data collection: Wanxi Qu, Rui Duan. Data analysis and interpretation: Xin Ding, Xin Wen, and Wanxi Qu. Manuscript preparation: Wanxi Qu. Manuscript revised: Wadih Issa, Xiuyu Ren, Zhen Ren. The first draft of the manuscript was written by Wanxi Qu and all authors commented on previous versions of the manuscript. All authors have read and approved the final manuscript. Wanxi Qu and Xin Wen contributed equally to this work. Acknowlegements We would like to thank the researchers for their contributions. References Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries [J]. CA Cancer J Clin. 2021;71(3):209–49. Ullah T, Patel H, Pena GM, et al. A contemporary review of radiation pneumonitis [J]. Curr Opin Pulm Med. 2020;26(4):321–5. Simone CB 2. Thoracic Radiation Normal Tissue Injury [J]. Semin Radiat Oncol. 2017;27(4):370–7. Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer [J]. N Engl J Med. 2021;384(13):1191–203. Shah MA, Bennouna J, Doi T, et al. KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma [J]. Future Oncol. 2021;17(10):1143–53. Wang H, Xu Y, Zuo F, et al. Immune-based combination therapy for esophageal cancer [J]. Front Immunol. 2022;13:1020290. Korpics MC, Katipally RR, Partouche J, et al. Predictors of Pneumonitis in Combined Thoracic Stereotactic Body Radiation Therapy and Immunotherapy [J]. Int J Radiat Oncol Biol Phys. 2022;114(4):645–54. Kroeze SG, Fritz C, Hoyer M, et al. Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review [J]. Cancer Treat Rev. 2017;53:25–37. Bi J, Qian J, Yang D, et al. Dosimetric Risk Factors for Acute Radiation Pneumonitis in Patients With Prior Receipt of Immune Checkpoint Inhibitors [J]. Front Immunol. 2021;12:828858. Lan K, Xu C, Liu S, et al. Modeling the risk of radiation pneumonitis in esophageal squamous cell carcinoma treated with definitive chemoradiotherapy [J]. Esophagus. 2021;18(4):861–71. Marks LB, Bentzen SM, Deasy JO, et al. Radiation dose-volume effects in the lung [J]. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S70–6. Sheng L, Zhuang L, Yang J, et al. Radiation pneumonia predictive model for radiotherapy in esophageal carcinoma patients [J]. BMC Cancer. 2023;23(1):988. Freites-Martinez A, Santana N, Arias-Santiago S, et al. Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies [J]. Actas Dermosifiliogr (Engl Ed). 2021;112(1):90–2. Salem ME, Puccini A, Xiu J, et al. Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma [J]. Oncologist. 2018;23(11):1319–27. Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial [J]. Lancet Oncol. 2019;20(11):1506–17. Rui-Hua Xu HL, Lu J, Bai Y, Mao T, Wang J, Fan Q, Zhang Y, Zhao K, Chen Z, Gao S, Li J, Fu Z, Gu K, Liu Z, Wu L, Zhang X, Zhu Y, Yang Q, Zou J. ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC) [Z]. J Clin Oncol. 2021 abstract 4000.https://doi.org/10.1200/JCO.2021.39.15_suppl.4000 . Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study [J]. Lancet. 2021;398(10302):759–71. Yoon HH, Jin Z, Kour O, et al. Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials [J]. JAMA Oncol. 2022;8(10):1456–65. Keffer S, Guy CL, Weiss E. Fatal Radiation Pneumonitis: Literature Review and Case Series [J]. Adv Radiat Oncol. 2020;5(2):238–49. Asakura H, Hashimoto T, Zenda S, et al. Analysis of dose-volume histogram parameters for radiation pneumonitis after definitive concurrent chemoradiotherapy for esophageal cancer [J]. Radiother Oncol. 2010;95(2):240–4. Xu C, Xi M, Moreno A, et al. Definitive Chemoradiation Therapy for Esophageal Cancer in the Elderly: Clinical Outcomes for Patients Exceeding 80 Years Old [J]. Int J Radiat Oncol Biol Phys. 2017;98(4):811–9. Tanabe S, Myojin M, Shimizu S, et al. Dose-volume analysis for respiratory toxicity in intrathoracic esophageal cancer patients treated with definitive chemoradiotherapy using extended fields [J]. J Radiat Res. 2013;54(6):1085–94. Zhao Y, Chen L, Zhang S, et al. Predictive factors for acute radiation pneumonitis in postoperative intensity modulated radiation therapy and volumetric modulated arc therapy of esophageal cancer [J]. Thorac Cancer. 2015;6(1):49–57. Lan K, Zhu J, Zhang J, et al. Propensity score-based comparison of survival and radiation pneumonitis after definitive chemoradiation for esophageal cancer: Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy [J]. Radiother Oncol. 2020;149:228–35. Inoo H, Sakanaka K, Fujii K, et al. Association of volumetric-modulated arc therapy with radiation pneumonitis in thoracic esophageal cancer [J]. J Radiat Res. 2022;63(4):646–56. Bradley J, Movsas B. Radiation pneumonitis and esophagitis in thoracic irradiation [J]. Cancer Treat Res. 2006;128:43–64. Bernchou U, Schytte T, Bertelsen A, et al. Time evolution of regional CT density changes in normal lung after IMRT for NSCLC [J]. Radiother Oncol. 2013;109(1):89–94. Huang BT, Lin PX, Wang Y et al. Developing a Prediction Model for Radiation Pneumonitis in Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy Combined With Clinical, Dosimetric Factors, and Laboratory Biomarkers [J]. Clin Lung Cancer, 2023, 24(8): e323-e31 e2. Abratt RP, Morgan GW, Silvestri G, et al. Pulmonary complications of radiation therapy [J]. Clin Chest Med. 2004;25(1):167–77. Fine A, Goldstein RH. The effect of transforming growth factor-beta on cell proliferation and collagen formation by lung fibroblasts [J]. J Biol Chem. 1987;262(8):3897–902. Guo L, Ding G, Xu W, et al. Prognostic biological factors of radiation pneumonitis after stereotactic body radiation therapy combined with pulmonary perfusion imaging [J]. Exp Ther Med. 2019;17(1):244–50. Hanania AN, Mainwaring W, Ghebre YT, et al. Radiation-Induced Lung Injury: Assess Manage [J] Chest. 2019;156(1):150–62. Dang J, Li G, Zang S, et al. Risk and predictors for early radiation pneumonitis in patients with stage III non-small cell lung cancer treated with concurrent or sequential chemoradiotherapy [J]. Radiat Oncol. 2014;9:172. Ren C, Ji T, Liu T, et al. The risk and predictors for severe radiation pneumonitis in lung cancer patients treated with thoracic reirradiation [J]. Radiat Oncol. 2018;13(1):69. Palma DA, Senan S, Tsujino K, et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis [J]. Int J Radiat Oncol Biol Phys. 2013;85(2):444–50. Watanabe S, Ogino I, Shigenaga D, et al. Relationship Between Radiation Pneumonitis Following Definitive Radiotherapy for Non-small Cell Lung Cancer and Isodose Line [J]. Vivo. 2021;35(6):3441–8. Tsujino K, Hashimoto T, Shimada T, et al. Combined analysis of V20, VS5, pulmonary fibrosis score on baseline computed tomography, and patient age improves prediction of severe radiation pneumonitis after concurrent chemoradiotherapy for locally advanced non-small-cell lung cancer [J]. J Thorac Oncol. 2014;9(7):983–90. Zhang XJ, Sun JG, Sun J, et al. Prediction of radiation pneumonitis in lung cancer patients: a systematic review [J]. J Cancer Res Clin Oncol. 2012;138(12):2103–16. Pinnix CC, Smith GL, Milgrom S, et al. Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma [J]. Int J Radiat Oncol Biol Phys. 2015;92(1):175–82. Tables Table 1 Baseline demographic and clinical characteristics of unresectable locally advanced EC patients treated with RT in the full analysis set. Baseline characteristics Baseline characteristics Sum (n = 92) RP ≥ grade 2 (n = 16, 17.39%) Non-RP 65 70 76.09 10 62.50 60 78.95 RP non-RP 76 82.61 0 0.00 76 100.00 RP 16 17.39 16 100.00 0 0.00 RP Grade 0–1 76 82.61 0 0.00 76 100.00 2 16 17.39 16 100.00 0 0.00 3 0 0.00 0 0.00 0 0.00 4 0 0.00 0 0.00 0 0.00 Gender Female 33 35.87 7 43.75 26 34.21 0.5696 Male 59 64.13 9 56.25 50 65.79 Smoke non-smoker 74 80.43 14 87.50 60 78.95 0.4332 smoker 18 19.57 2 12.50 16 21.05 Pathology squamous carcinoma 88 95.65 15 93.75 73 96.05 0.5408 other 4 4.35 1 6.25 3 3.95 Location cervical EC 3 3.26 0 0.00 3 3.95 0.9704 Upper thoracic EC 10 10.87 2 12.50 8 10.53 Middle thoracic EC 53 57.61 9 56.25 44 57.89 Lower thoracic EC 24 26.09 5 31.25 19 25.00 Other 2 2.17 0 0.00 2 2.63 cTNM I 8 8.70 1 6.25 7 9.21 > 0.99 II 15 16.30 3 18.75 12 15.79 III 51 55.43 9 56.25 42 55.26 IV 18 19.57 3 18.75 15 19.74 T stage 1 8 8.70 1 6.25 7 9.21 0.5854 2 14 15.22 1 6.25 13 17.11 3 15 16.30 4 25.00 11 14.47 4 55 59.78 10 62.50 45 59.21 N stage 0 28 30.43 4 25.00 24 31.58 0.2503 1 45 48.91 7 43.75 38 50.00 2 18 19.57 4 25.00 14 18.42 3 1 1.09 1 6.25 0 0.00 M stage 0 77 83.70 15 93.75 62 81.58 0.4551 1 15 16.30 1 6.25 14 18.42 Table 2 Baseline demographic and clinical characteristics of unresectable locally advanced EC patients treated with immunotherapy and RT in the full analysis set. Baseline characteristics Sum (n = 84) RP ≥ grade 2 (n = 26, 30.95%) Non-RP 65 66 78.57 15 57.69 51 87.93 RP non-RP 58 69.05 0 0.00 58 100.00 RP 26 30.95 26 100.00 0 0.00 RP Grade 0–1 58 69.05 0 0.00 58 100.00 2 23 27.06 23 88.46 0 0.00 3 1 1.18 1 3.85 0 0.00 4 2 2.35 2 7.69 0 0.00 Gender Female 27 32.14 7 26.92 20 34.48 0.4928 Male 57 67.86 19 73.08 38 65.52 Smoke non-smoker 68 80.95 18 69.23 50 86.21 0.0670 smoker 16 19.05 8 30.77 8 13.79 Pathology squamous cell carcinoma 82 97.62 26 100.00 56 96.55 1 other 2 2.35 0 0.00 2 3.57 Location Cervical EC 2 2.38 1 3.85 1 1.72 0.9669 Upper thoracic EC 11 13.10 3 11.54 8 13.79 Middle thoracic EC 46 54.76 15 57.69 31 53.45 Lower thoracic EC 16 19.05 5 19.23 11 18.97 Other 9 10.71 2 7.69 7 12.07 Immunotherapy drugs atezolizumab 4 4.76 2 7.69 2 3.45 0.1500 camrelizumab 28 33.33 9 34.62 19 32.76 pembrolizumab 9 10.71 2 7.69 7 12.07 toripalimab 4 4.76 1 3.85 3 5.17 tislelizumab 29 34.52 12 46.15 17 29.31 sintilimab 10 11.91 0 0.00 10 17.24 Immunotherapy type PD-1 80 95.24 24 92.31 56 96.55 0.5842 PD-L1 4 4.76 2 7.69 2 3.45 Sequence of RT and immunotherapy Concurrent 43 50.59 17 65.38 26 44.83 0.1506 RT first 32 37.65 6 23.08 26 44.83 immunotherapy first 9 11.76 3 11.54 6 10.34 cTNM I 2 2.38 1 3.85 1 1.72 0.5167 II 10 11.91 2 7.69 8 13.80 III 25 29.76 10 38.46 15 25.86 IV 47 55.95 13 50.00 34 58.62 T stage 1 4 4.76 2 7.69 2 3.45 0.2894 2 14 16.67 3 11.54 11 18.97 3 26 30.95 11 42.31 15 25.86 4 40 47.62 10 38.46 30 51.72 N stage 0 19 22.62 7 26.92 12 20.69 0.5168 1 37 44.05 9 34.62 28 48.28 2 28 33.33 10 38.46 18 31.03 M stage 0 69 82.14 22 84.62 47 81.03 0.7683 1 15 17.86 4 15.38 11 18.97 Irradiation segmentation dose (Gy) 1.8 40 47.62 15 57.69 25 43.10 0.4415 2.0 19 22.62 4 15.38 15 25.86 1.8 + 2.0 25 29.76 7 26.92 18 31.03 Data are n (100%). Table 3A Logistic regression analysis of clinical parameters associated with RP among patients treated with RT. Clinical parameters p-value OR 95% CI Upper Down Age 0.252 0.958 0.89 1.031 TD 0.284 1.098 0.925 1.303 PTV 0.245 1.003 0.998 1.007 MLD 0.624 1.007 0.98 1.034 V5 0.568 0.915 0.674 1.241 V10 0.349 1.267 0.772 2.08 V15 0.089 0.527 0.252 1.101 V20 0.098 2.075 0.874 4.927 V25 0.459 0.659 0.219 1.987 V30 0.934 0.962 0.384 2.408 Table 3B Logistic regression analysis of clinical parameters associated with RP among patients treated with RT and immunotherapy. Clinical parameters p-value OR 95% CI Upper Down Age 0.010 0.976 0.892 0.815 Total irradiation dose 0.036 1.603 1.277 1.016 irradiation segmentation frequency 0.009 0.903 0.665 0.49 GTVp 0.355 1.014 0.988 0.963 PTV 0.205 1.009 1.003 0.998 MLD 0.752 1.012 1.002 0.991 V5 0.562 1.04 1.009 0.979 V10 0.519 1.503 1.106 0.814 V15 0.043 0.98 0.507 0.262 V20 0.155 5.358 2.026 0.766 V25 0.651 2.164 0.793 0.291 V30 0.974 1.607 0.992 0.613 Abbreviations: OR: Odds ratio; CI: Confidence interval; GTVp: gross tumor volume (the primary esophageal mass volume based on imaging studies); PTV: planning target volume; MLD: mean lung dose; Vx: volume of lung receiving ≥ x Gy. Table 4 A Clinical parameters selected to construct RP risk model by multivariate Cox regression analysis among patients treated with RT. Clinical parameters Coef HR 95% CI P-value HR.95L HR.95H Age -0.0594 0.9423 0.8968 0.9902 0.0188 N 0.6899 1.9935 0.9852 4.0338 0.0551 M -1.8524 0.1569 0.0194 1.2713 0.0827 V20 0.1205 1.1281 1.0175 1.2506 0.0220 Abbreviations: HR: Hazard ratio; CI: Confidence interval; Coef: coefficient value. Table 4 B Clinical parameters selected to construct RP risk model by multivariate Cox regression analysis among patients treated with RT and immunotherapy. Clinical parameters Coef HR 95% CI P-value HR.95L HR.95H Age -0.0555 0.9460 0.8996 0.9949 0.0308 Total irradiation dose 0.1292 1.1379 0.9834 1.3166 0.0827 Irradiation segmentation Frequency -0.2191 0.8033 0.6651 0.9702 0.0229 V15 -0.2134 0.8078 0.6562 0.9945 0.0443 V20 0.2214 1.2478 0.9712 1.6034 0.0834 Abbreviations: HR: Hazard ratio; CI: Confidence interval; Coef: coefficient value. Additional Declarations No competing interests reported. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4345357","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":297903759,"identity":"a8de3200-bb86-4fe4-9c26-7196880aa837","order_by":0,"name":"Wanxi Qu","email":"","orcid":"","institution":"Xuzhou Medical University","correspondingAuthor":false,"prefix":"","firstName":"Wanxi","middleName":"","lastName":"Qu","suffix":""},{"id":297903760,"identity":"52bb0bac-cfd0-4f3b-bf35-1c9ffe3a31eb","order_by":1,"name":"Xin Wen","email":"","orcid":"","institution":"Xuzhou Medical University","correspondingAuthor":false,"prefix":"","firstName":"Xin","middleName":"","lastName":"Wen","suffix":""},{"id":297903761,"identity":"cfd79693-df17-4ad6-b9bd-103b8d0034a7","order_by":2,"name":"Rui Duan","email":"","orcid":"","institution":"Xuzhou Medical University","correspondingAuthor":false,"prefix":"","firstName":"Rui","middleName":"","lastName":"Duan","suffix":""},{"id":297903763,"identity":"7ad9046f-4621-490d-ab1e-45d51f16a994","order_by":3,"name":"Wadih Issa","email":"","orcid":"","institution":"The University of Texas Southwestern Medical Center","correspondingAuthor":false,"prefix":"","firstName":"Wadih","middleName":"","lastName":"Issa","suffix":""},{"id":297903765,"identity":"0b4d6c43-2764-4201-a466-70d50217d7a6","order_by":4,"name":"Xiuyu Ren","email":"","orcid":"","institution":"Xuzhou Medical University","correspondingAuthor":false,"prefix":"","firstName":"Xiuyu","middleName":"","lastName":"Ren","suffix":""},{"id":297903767,"identity":"18c4dbed-1e7f-4632-a2e9-ab6623d8b4b5","order_by":5,"name":"Zhen Ren","email":"","orcid":"","institution":"Xuzhou Medical University","correspondingAuthor":false,"prefix":"","firstName":"Zhen","middleName":"","lastName":"Ren","suffix":""},{"id":297903769,"identity":"22da79e2-20a0-4bed-9ef7-7ee6622898f8","order_by":6,"name":"Longzhen Zhang","email":"","orcid":"","institution":"Affiliated Hospital of Xuzhou Medical University","correspondingAuthor":false,"prefix":"","firstName":"Longzhen","middleName":"","lastName":"Zhang","suffix":""},{"id":297903771,"identity":"b389db6c-dc82-47ad-90b5-22bb9a47fffb","order_by":7,"name":"Xin Ding","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAAyElEQVRIiWNgGAWjYDCCwyDCgEGOjb2x8eEHUrQY8/EcbjaWIErLAQiVOE8ivU2AhxgdfMd5D7/mKbhjzCb5sI1BgsFOTreBgBbJw3xpljMMnsmxSSe2PShgSDY2O0BAi8FhHjODDwaHjYFa2g0kGA4kbiNKS4LB4cQ2yYNtEjxEajF+8AGkRYKRSC2SQFsYZ4AcxpMIDGQDIvzCd/6M8WeeP4fl5NuPP3z4ocJOjqAWIGBDikADwspBgJm4ZDIKRsEoGAUjFwAAU6tArZ8r6QgAAAAASUVORK5CYII=","orcid":"","institution":"Affiliated Hospital of Xuzhou Medical University","correspondingAuthor":true,"prefix":"","firstName":"Xin","middleName":"","lastName":"Ding","suffix":""}],"badges":[],"createdAt":"2024-04-30 00:24:53","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4345357/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4345357/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":56198635,"identity":"1ce21cb5-8cff-463c-963a-0dee09e1af0b","added_by":"auto","created_at":"2024-05-09 18:38:03","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":435372,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eThe workflow diagram of this study.\u003c/strong\u003e EC: Esophageal carcinoma; RT: radiation therapy; RP: radiation pneumonities.\u003c/p\u003e","description":"","filename":"Figure1.png","url":"https://assets-eu.researchsquare.com/files/rs-4345357/v1/a1c2bc8b132d4f38fba219d2.png"},{"id":56198312,"identity":"96ae97d2-ffcc-41b9-b084-69f7c1957e4c","added_by":"auto","created_at":"2024-05-09 18:30:03","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":609254,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eConstruction of RP risk model in EC patients received RT.\u003c/strong\u003e (a) Clinical parameters selected to construct RP risk model; (b) ROC curve for satisfactory accuracy with AUC=0.734; (c) Risk curves in RP risk model.\u003c/p\u003e","description":"","filename":"Figure2.png","url":"https://assets-eu.researchsquare.com/files/rs-4345357/v1/88ade431b423cd521dd0e920.png"},{"id":56197195,"identity":"77ee02cf-ca91-4409-9cfa-32ce89377881","added_by":"auto","created_at":"2024-05-09 18:22:02","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":753790,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eConstruction of RP risk model in EC patients received RT and immunotherapy.\u003c/strong\u003e (a) Clinical parameters selected to construct RP risk model; (b) ROC curve for satisfactory accuracy with AUC=0.805; (c) Risk curves in RP risk model; (d) Clinical correlation of risk score.\u003c/p\u003e","description":"","filename":"Figure3.png","url":"https://assets-eu.researchsquare.com/files/rs-4345357/v1/6ccaa0edf0aaaa1819ea0751.png"},{"id":59396799,"identity":"0e6240c8-bbc5-40b7-8e13-34849e4747d0","added_by":"auto","created_at":"2024-07-01 09:20:39","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":3137306,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4345357/v1/462f5e48-d5c0-42e4-9163-40328f9ca649.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Predictive risk model for radiation-induced pneumonitis in patients diagnosed with advanced esophageal cancer receiving radiation therapy alone or in combination with immunotherapy: A retrospective study","fulltext":[{"header":"1. Introduction","content":"\u003cp\u003eAccording to the GLOBOCAN 2020 estimates, esophageal cancer (EC) ranks seventh in terms of incidence and sixth in mortality overall \u003csup\u003e[\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]\u003c/sup\u003e. Radiation therapy (RT) plays a vital role in the management of EC especially in unresectable locally advanced disease. Radiation induced pneumonitis (RP), is one of the most common related adverse event in patients with EC due to the anatomical proximity to the lungs\u003csup\u003e[\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]\u003c/sup\u003e, \u003csup\u003e[\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eIn recent years, immunotherapy either alone or in combination with RT has become widely applied to patients with EC\u003csup\u003e[\u003cspan additionalcitationids=\"CR5\" citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e]\u003c/sup\u003e. With the extensive use of RT and immunotherapy in these patients, and the well-established induced pneumonitis caused by each treatment alone, a new question concerning the incidence of RP in patients receiving the combination of RT and immunotherapy arises. Some reports suggested that the incidence of RP increased with the combination\u003csup\u003e[\u003cspan additionalcitationids=\"CR8\" citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]\u003c/sup\u003e, while other noted no significant difference. Moreover, several parameters were established to be predictors of RP, including V5, V10, V20 and mean lung dose (MLD)\u003csup\u003e[\u003cspan additionalcitationids=\"CR11\" citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e]\u003c/sup\u003e. However, these parameters did not taken immunotherapy into consideration.\u003c/p\u003e \u003cp\u003eIn this study, we evaluated the incidence of RP in patients with EC who received RT alone compared to patients who received the combination of RT and immunotherapy, and we constructed a model to predict the accuracy of RP in EC patients who received the combination of immunotherapy and RT, using clinical parameters known to be associated with RP, which could provide an effective tool for individualized risk assessment of symptomatic RP (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e"},{"header":"2. Materials and methods","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003e2.1. Data extraction and inclusion criterias\u003c/h2\u003e \u003cp\u003eThis retrospective study was conducted at the Affiliated of Xuzhou Medical University. Patients diagnosed with EC and receiving RT alone or in combination with immunotherapy between 1/2020 and 7/2023 were included. Inclusion criterias were: patients older than 18 years old, a confirmed pathology report of esophageal squamous carcinoma, to have received both immunotherapy, completion of thoracic radiotherapy and to have at least one baseline and at least one follow-up chest CT scan after RT. Exclusion criterias included active coexisting cancer, chronic lung infection before radiotherapy initiation and developing after 180 days of starting RT. Patients with incomplete or missing data were excluded. Clinical data including, baseline characteristics, comorbidities, tumor pathological and radiographical characteristics, treatment summary and dose and volume histogram (DVH) factors (GTV (gross tumor volume), PTV (planning target volume), MLD, V5/10/15/20/25/30), were extracted from electronic medical records. Vx was defined as the percentage of lung volume receiving\u0026thinsp;\u0026ge;\u0026thinsp;x Gy. The following dosimetric parameters were generated based on the DVH of the lung-PTV, including the total dose of radiotherapy, GTVp, PTV, MLD and bilateral lungs V5/10/15/20/25/30. All DVH parameters were extracted and calculated from the planned dose distribution according to the Treatment Planning System.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003e2.2. Treatment\u003c/h2\u003e \u003cp\u003eAll patients received fixed-field intensity modulated radiotherapy (IMRT). The delineation of the target area was based on upper gastrointestinal radiography, CT findings and (or) positron emission tomography-computed tomography. In our study, GTVp was defined as the primary esophageal mass volume based on imaging studies. The CTV was defined as 3.0 cm outward in the up and down direction of GTVp and 0.5\u0026ndash;0.6 cm outward in the anterior-posterior and left-right directions plus the lymph node area where the metastatic lymph nodes were located. The PTV was defined as the CTV plus 0.5\u0026ndash;0.8 cm margins to account for mechanical instability, esophageal tumor movement and respiratory motion. The prescribed doses were 50 to 64.4 Gy at 1.8 to 2.0 Gy per fraction once daily and 5 fractions per week. The boundaries of organs at risk were refered to the Radiotherapy and Oncology Group guidelines.\u003c/p\u003e \u003cp\u003eAll EC patients were treated with programmed death-1 (PD-1)/ programmed death ligand 1 (PD-L1) inhibitors including camrelizumab, atezolizumab, pembrolizumab, toripalimab, tislelizumab, and sintilimab. All the doses and adjustments to the immunotherapy regimen followed the National Comprehensive Cancer Network (NCCN) guidelines.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec5\" class=\"Section2\"\u003e \u003ch2\u003e2.4 Assessments of RP\u003c/h2\u003e \u003cp\u003eThe diagnosis of RP was confirmed by clinical symptoms and abnormal lung CT images based on the history of RT in the past 6 months, which cannot be attributed to infection, checkpoint inhibitor-related pneumonitis (CIP) or other diseases. Clinical symptoms includes worsening dyspnea, an associated nonproductive cough, low-grade fevers, mild chest pain, malaise and weight loss\u003csup\u003e[\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]\u003c/sup\u003e and abnormal lung CT images are visualized with diffuse lung abnormalities or fibrosis limited or most to the radiation field of the lung. The severity of RP was assessed by National Cancer Institute\u0026rsquo;s Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0\u003csup\u003e[\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e, \u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e]\u003c/sup\u003e. The endpoint was the presence of grade\u0026thinsp;\u0026ge;\u0026thinsp;2 RP occurring within 6 months (180 days) after RT.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec6\" class=\"Section2\"\u003e \u003ch2\u003e2.5 Models construction\u003c/h2\u003e \u003cp\u003e25 clinical parameters (age, smoke, gender, pathological type, location, immunotherapy drug, immunotherapy drug type, immunotherapy cycles, sequence, cTNM, T stage, N stage, M stage, total irradiation dose, irradiation segmentation dose, irradiation segmentation frequency, GTVp, PTV, MLD, V5, V10, V15, V20, V25, V30) were included for construction of RP Risk Model by multivariate Cox regression with R (V.4.3.3) vision. Risk scores were calculated by the following formulation: Risk score=\u003cspan class=\"InlineEquation\"\u003e\u003cspan class=\"mathinline\"\u003e\\({\\sum }_{1}^{\\text{n}}\\text{c}\\text{o}\\text{e}\\text{f}\\times {\\text{f}\\text{a}\\text{c}\\text{t}\\text{o}\\text{r}}_{\\text{n}}\\)\u003c/span\u003e\u003c/span\u003e, where coef means the coefficient value, factor means clinical paraments used for model construction and n means the number of modeling clinical paraments. ROC curve (AUC value) and risk curves were visualized by \u0026ldquo;survival ROC\u0026rdquo; package for evaluating the accuracy of RP risk model. AUC value more than 0.7 confirms the satisfied accuracy. All EC patients were classified into two cohorts according to their risk score and the cut value was the media risk scores. The relationship of risk score and clinical parameters was analyzed by cox regression analysis with \u0026ldquo;bees warm\u0026rdquo; package.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec7\" class=\"Section2\"\u003e \u003ch2\u003e2.6 Statistical analysis\u003c/h2\u003e \u003cp\u003eData analysis was conducted using the Statistical Package for Social Sciences (SPSS, version 29.0). The χ\u003csup\u003e2\u003c/sup\u003e test and Logistic regression analysis were used to analyze the relationship of categorical variables and continuous variables with RP occurrence respectively. \u003cem\u003eP\u003c/em\u003e-values\u0026thinsp;\u0026lt;\u0026thinsp;0.05 were considered statistically significant.\u003c/p\u003e \u003c/div\u003e"},{"header":"3. Results","content":"\u003cdiv id=\"Sec9\" class=\"Section2\"\u003e \u003ch2\u003e3.1. Patient characteristics\u003c/h2\u003e \u003cp\u003eFrom 5/2020 to 7/2023, a total of 225 patients diagnosed with EC were identified. 115 patients received RT alone (RT group) and 110 EC patients received of RT\u0026thinsp;+\u0026thinsp;immunotherapy (RT-I group). Of the 115 EC patients having received RT alone, 17 cases undergone surgery, 5 cases were lost to follow-up and 1 case received incomplete RT, were excluded. Of the 110 EC patients having received RT\u0026thinsp;+\u0026thinsp;Immunotherapy, 12 undergone surgery, 6 cases were diagnosed with RP after 180 days, 3 cases received incomplete RT and 5 cases were lost to follow-up were excluded. In summary, only 92 patients receiving RT alone and 84 patients receiving RT\u0026thinsp;+\u0026thinsp;Immunotherapy were eligible for inclusion in this study. The characteristics of the eligible patients were summarized in Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e \u0026amp; Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e.\u003c/p\u003e\u003cp\u003eThere are 59 males (64.13%) and 33 females (35.87%) with the median age of 70.9 years (range 49\u0026ndash;79) in group RT, while 57 males (67.86%) and 27 females (32.14%), with the median age of 69.8 (range, 48\u0026ndash;86) years in group RT-I. In general, a larger proportion of EC patients is male (64.13% and 67.86% in group RT and RT-I respectively), with no smoking history (80.43% and 80.95% in group RT and RT-I respectively), located in the middle thoracic (57.61% and 54.76% in group RT and RT-I respectively. All patients received chemotherapy in both groups. Most patients who received immunotherapy were treated with PD-1 inhibitors (95.24%), such as camrelizumab, pembrolizumab, toripalimab, tislelizumab and sintilimab. 50.59% of patients in the RT-I group received concurrent treatment, which is defined as receiving immunotherapy within 30 days of starting RT, and 37.65% of patients received RT prior to immunotherapy.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec10\" class=\"Section2\"\u003e \u003ch2\u003e3.2 RP incidence\u003c/h2\u003e \u003cp\u003eA total of 16 patients (17.39%) who received RT alone and 26 patients (30.95%) who received RT\u0026thinsp;+\u0026thinsp;Immunotherapy and fited the inclusion criteria cited in the method part had a RP. A significant difference between the two groups existed (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.035), suggesting that immunotherapy may increase the risk of RP. Moreover, all patients who received RT alone had a grade 2 RP with the median interval time of 87 days (range, 41\u0026ndash;151 days) while 26 RP patients in group RT-I were consisting of 23 cases of grade 2 (88.5%), 1 cases of grade 3 (3.8%) and 2 cases of grade 4 (7.7%) with the median interval time of 106 days (range, 34\u0026ndash;171 days).\u003c/p\u003e \u003cp\u003eFurther analysis showed that clinical characteristics such as age, the total irradiation dose, irradiation segmentation frequency and V15 were in positively correlated with the risk of RP occurrence in group RT-I (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.017, \u003cem\u003eP\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.020, \u003cem\u003eP\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.012, \u003cem\u003eP\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.039 respectively) (Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e \u0026amp; Table\u0026nbsp;\u003cspan refid=\"Tab5\" class=\"InternalRef\"\u003e3\u003c/span\u003eB). However, no clinical features have been shown to be significantly associated with RP (Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e \u0026amp; Table\u0026nbsp;\u003cspan refid=\"Tab5\" class=\"InternalRef\"\u003e3\u003c/span\u003eA) in group RT.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec11\" class=\"Section2\"\u003e \u003ch2\u003e3.3. Construction of RP Risk Model in EC patients\u003c/h2\u003e \u003cp\u003eSeveral factors were included for the construction of RP Risk Model by multivariate Cox regression in group RT and RT-I seperatly. Four factors were used for RP prediction risk model in patients who received the RT alone, including age, N, M and V20 with the following formula: Risk score = (-0.0594\u0026times;age) +(0.6899\u0026times;N stage) + (-1.8524\u0026times;M stage) + (0.1205\u0026times;V20) (Table\u0026nbsp;\u003cspan refid=\"Tab4\" class=\"InternalRef\"\u003e4\u003c/span\u003eA and Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eA). Meanwhile, five factors were used for RP prediction risk model in patients who received the RT\u0026thinsp;+\u0026thinsp;Immunotherapy (group RT-I): age, total irradiation dose, irradiation segmentation frequency, V15 and V20. The formula was: Risk score = (-0.0555\u0026times;age) + (0.1291\u0026times;total irradiation dose) + (-0.2190\u0026times;irradiation segmentation frequency) + ( -0.2134\u0026times;V15) + (0.2214\u0026times;V20) (Table\u0026nbsp;\u003cspan refid=\"Tab4\" class=\"InternalRef\"\u003e4\u003c/span\u003eB, Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eA). N and M stage were assigned as categorical variable while age, total irradiation dose, irradiation segmentation frequency, V15 and V20 were assigned as numerical variable.\u003c/p\u003e \u003cp\u003eThe ROC curve indicated the satisfactory accuracy with AUC value was 0.734 and 0.805 in group RT and RT-I respectively (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eB \u0026amp; Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eB). Furthermore, Risk curves confirmed favorable accuracy that the higher risk score, the higher RP risk, the lower interval times when RP happens after RT (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eC \u0026amp; Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eC). We further analyzed the clinical correlation of risk score in EC patients by univariable analysis. Figure showed that risk score was highly interdependent with immunotherapy drug (\u003cem\u003eP\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.000017 respectively) (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eD).\u003c/p\u003e \u003c/div\u003e"},{"header":"4. Discussion","content":"\u003cp\u003eTumor-cell PD-L1 is expressed in 50% of patients with advanced EC\u003csup\u003e[\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e, \u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e]\u003c/sup\u003e. While the major clinical benefits reported from the use of PD-1/PD-L1 inhibitors\u003csup\u003e[\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e, \u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e]\u003c/sup\u003e, the accompanying risk of adverse events cannot be underestimated\u003csup\u003e[\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e]\u003c/sup\u003e. RP is a common adverse event occurring in 10\u0026ndash;30% of patients with chest malignancies treated with RT\u003csup\u003e[\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e, \u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e]\u003c/sup\u003e. Many clinical factors such as age, smoking history, the size of tumor, MLD, V20 and the lung volume receiving low-dose irradiation are known to be independent risk factor for the occurence of RP\u003csup\u003e[\u003cspan additionalcitationids=\"CR21 CR22 CR23 CR24\" citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e]\u003c/sup\u003e. However, the introduction of immunotherapy to the standard of care in this population should lead to the re-assessment of this pattern.\u003c/p\u003e \u003cp\u003eIn our study, the incidence of grade\u0026thinsp;\u0026ge;\u0026thinsp;2 RP in patients with EC who received RT and immunotherapy was 30.95%, which is higher compared to those who received RT alone (17.39%). Most RP occurred 106 days after RT, which was consistent with previous studies\u003csup\u003e[\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e, \u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e]\u003c/sup\u003e, however patient who received RT alone developed a delayed RP compared to those in the RT-I group (87 days).\u003c/p\u003e \u003cp\u003eAge, the total irradiation dose, irradiation segmentation frequency and V15 are independent predictive factors for the development of grade\u0026thinsp;\u0026ge;\u0026thinsp;2 RP in patients with unresectable locally advanced EC receiving RT\u0026thinsp;+\u0026thinsp;Immunotherapy. Age was shown to be negatively associated with the development of RP in patients with EC in our study, which is comparable to patients with lung cancer who received chest irradiation\u003csup\u003e[\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e]\u003c/sup\u003e. Younger age group may possess a stronger immune response than older patients, which account for the higher risk of RP. Cytokines such as tumor necrosis factor alpha (TNF-α), transforming growth factor beta (TGF-β), interleukin (IL)-1, IL-6 as well as reactive oxygen and growth factors released from irradiated lung cells further recruit inflammatory cells to alveoli, which could lead to the development of an acute-phase pneumonitis\u003csup\u003e[\u003cspan additionalcitationids=\"CR30\" citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e]\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eInterestingly, although a non-smoking status showed a trend to be protective from the development of RP, the statistical analysis was not significant, which may be accountable to the small cohort size. Besides, RP is associate with a radiation therapy in a dose dependent manner, which was consistent with our analysis showing that higher total irradiation doses are associated with a higher risk of RP \u003csup\u003e[\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e]\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003e The NCCN guidelines (Version 1.2023) recommend that the lung dose limits for EC patients are as follows: V5\u0026thinsp;\u0026le;\u0026thinsp;50%, V10\u0026thinsp;\u0026le;\u0026thinsp;40%, V20\u0026thinsp;\u0026le;\u0026thinsp;20%, V30\u0026thinsp;\u0026le;\u0026thinsp;15%, and V40\u0026thinsp;\u0026le;\u0026thinsp;10%. V5, V20, V30, and MLD have been identified as independent predictors of RP\u003csup\u003e[\u003cspan additionalcitationids=\"CR34\" citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e]\u003c/sup\u003e. In our study, V15 was found to be related with RP occurrence, which was reported in the literature in predicting the development of grade\u0026thinsp;\u0026ge;\u0026thinsp;2 RP\u003csup\u003e[\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e]\u003c/sup\u003e. V15 may be an important factor to consider when discussing the benefits and adverse events that may occur after receiving RT\u0026thinsp;+\u0026thinsp;Immunotherapy.\u003c/p\u003e \u003cp\u003eIn order to construct an optimistic RP prediction risk model, all clinical parameters were included in R vision for cyclic modeling inspection. Ultimately, four and five parameters were screen out in two groups. Several studies tried to establish a risk model including only one parameter: V20. Current studies showed that V20\u0026thinsp;\u0026gt;\u0026thinsp;20% was a risk factor for RP\u003csup\u003e[\u003cspan additionalcitationids=\"CR38\" citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e]\u003c/sup\u003e, however we found that 69% of RP cases occurred with a V20\u0026thinsp;\u0026le;\u0026thinsp;20% in patients receiving RT alone. Our risk model combines several factor to predict the risk of RP however larger cohort are required to reevaluate the predictive value of a V20\u0026gt;20% when combined with other factors age and N, M stage. In EC patients who received RT\u0026thinsp;+\u0026thinsp;immunotherapy, more paraments should be included for RP risk prediction. Except for four parameters which are significantly related to RP occurrence (age, total irradiation dose, irradiation segmentation frequency and V15), V20 was also included in RP prediction risk model. According to the coefficient value, the smaller number of irradiation segmentation frequency, the higher total irradiation dose, the higher incidence of RP. It is easy to be explained that lung tissue belongs to late responding tissue, which is more sensitive to single dose.\u003c/p\u003e \u003cp\u003eIn summary, age and V20 are very important parameters for predicting RP risk. Whether EC patients received immunotherapy or not, age and V20 were typical factors to be evaluate while establishing the treatment plan and calculating the RP incidence risk. In the era of immunotherapy, age, total RT dose, irradiation segmentation frequency, V15 and V20 should be reevaluated.\u003c/p\u003e \u003cp\u003eNevertheless, our study encountered several limitations. Including the retrospective design and the fact that all the patients received chemotherapy. Therefore, no comparison of differences in various chemotherapy regimens were available. In addition, the majority of patients included in this study were diagnosed with squamous carcinomas, which are more common in China, compared to adenocarcinomas, which are more prevalent in Europe and the United States. Therefore, the probability of RP and the risk factors for adenocarcinoma of the esophagus in the real world needs to be further explored.\u003c/p\u003e"},{"header":"5. Conclusions","content":"\u003cp\u003eWith the increasing use of immunotherapy in combination with radiation therapy in patients with advanced EC, we showed an increased incidence of RP in patients receiving RT\u0026thinsp;+\u0026thinsp;Immunotherapy compared to patients who received RT alone. We further analyzed clinical parameters associated with RP and constructed a RP prediction risk model consisting of five parameters in EC patients, which may provide a basis for revising lung dose constraints in efforts to better prevent RP. Larger cohorts and prospective studies are required to establish and validate a new definitive model risk for patients with EC receiving the combination of RT\u0026thinsp;+\u0026thinsp;Immotherapy which could enable better treatment planning for this population\u003c/p\u003e"},{"header":"List Of Abbreviations","content":"\u003cp\u003eRT (radiation therapy)；RP (radiation induced pneumonitis)； EC (esophageal cancer); MLD (mean lung dose); GTV (gross tumor volume); PTV (planning target volume); DVH (dose and volume histogram); IMRT (intensity modulated radiotherapy); PD-1 (programmed death-1); PD-L1 (programmed death ligand 1); CIP (checkpoint inhibitor-related pneumonitis); TNF-\u0026alpha; (transforming growth factor alpha); TGF-\u0026beta;(transforming growth factor beta); IL (interleukin); CTCAE (Common Terminology Criteria for Adverse Events); NCCN (National Comprehensive Cancer Network)\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003e\u003cem\u003eEthics approval and consent to participate\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis study was approved by the affiliated hospital of Xuzhou medical university research ethics board (XYFY2020-YL009).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eConsent for publication\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eAvaliability of date and materials\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eCompeting interests\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eFunding\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis work was supported by Xuzhou special fund in scientific and technological innovation promotion (KC23266) and the Introduction of Specialist Team in Clinical Medicine of Xuzhou (2019TD003).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eAthors\u0026rsquo; contributions\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll authors contributed to the study conception and design. Study design: Xin Ding, Longzhen Zhang and Wanxi Qu. Data collection: Wanxi Qu, Rui Duan. Data analysis and interpretation: Xin Ding, Xin Wen, and Wanxi Qu. Manuscript preparation: Wanxi Qu. Manuscript revised: Wadih Issa, Xiuyu Ren, Zhen Ren. The first draft of the manuscript was written by Wanxi Qu and all authors commented on previous versions of the manuscript. All authors have read and approved the final manuscript. Wanxi Qu and Xin Wen contributed equally to this work.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowlegements\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eWe would like to thank the researchers for their contributions.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eSung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries [J]. CA Cancer J Clin. 2021;71(3):209\u0026ndash;49.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eUllah T, Patel H, Pena GM, et al. A contemporary review of radiation pneumonitis [J]. Curr Opin Pulm Med. 2020;26(4):321\u0026ndash;5.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSimone CB 2. Thoracic Radiation Normal Tissue Injury [J]. Semin Radiat Oncol. 2017;27(4):370\u0026ndash;7.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer [J]. N Engl J Med. 2021;384(13):1191\u0026ndash;203.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eShah MA, Bennouna J, Doi T, et al. KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma [J]. Future Oncol. 2021;17(10):1143\u0026ndash;53.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWang H, Xu Y, Zuo F, et al. Immune-based combination therapy for esophageal cancer [J]. Front Immunol. 2022;13:1020290.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKorpics MC, Katipally RR, Partouche J, et al. Predictors of Pneumonitis in Combined Thoracic Stereotactic Body Radiation Therapy and Immunotherapy [J]. Int J Radiat Oncol Biol Phys. 2022;114(4):645\u0026ndash;54.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKroeze SG, Fritz C, Hoyer M, et al. Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review [J]. Cancer Treat Rev. 2017;53:25\u0026ndash;37.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBi J, Qian J, Yang D, et al. Dosimetric Risk Factors for Acute Radiation Pneumonitis in Patients With Prior Receipt of Immune Checkpoint Inhibitors [J]. Front Immunol. 2021;12:828858.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLan K, Xu C, Liu S, et al. Modeling the risk of radiation pneumonitis in esophageal squamous cell carcinoma treated with definitive chemoradiotherapy [J]. Esophagus. 2021;18(4):861\u0026ndash;71.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMarks LB, Bentzen SM, Deasy JO, et al. Radiation dose-volume effects in the lung [J]. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S70\u0026ndash;6.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSheng L, Zhuang L, Yang J, et al. Radiation pneumonia predictive model for radiotherapy in esophageal carcinoma patients [J]. BMC Cancer. 2023;23(1):988.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFreites-Martinez A, Santana N, Arias-Santiago S, et al. Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies [J]. Actas Dermosifiliogr (Engl Ed). 2021;112(1):90\u0026ndash;2.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSalem ME, Puccini A, Xiu J, et al. Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma [J]. Oncologist. 2018;23(11):1319\u0026ndash;27.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial [J]. Lancet Oncol. 2019;20(11):1506\u0026ndash;17.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRui-Hua Xu HL, Lu J, Bai Y, Mao T, Wang J, Fan Q, Zhang Y, Zhao K, Chen Z, Gao S, Li J, Fu Z, Gu K, Liu Z, Wu L, Zhang X, Zhu Y, Yang Q, Zou J. ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC) [Z]. J Clin Oncol. 2021\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003eabstract 4000.https://doi.org/10.1200/JCO.2021.39.15_suppl.4000\u003c/span\u003e\u003cspan address=\"abstract 4000.10.1200/JCO.2021.39.15_suppl.4000\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study [J]. Lancet. 2021;398(10302):759\u0026ndash;71.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYoon HH, Jin Z, Kour O, et al. Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials [J]. JAMA Oncol. 2022;8(10):1456\u0026ndash;65.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKeffer S, Guy CL, Weiss E. Fatal Radiation Pneumonitis: Literature Review and Case Series [J]. Adv Radiat Oncol. 2020;5(2):238\u0026ndash;49.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAsakura H, Hashimoto T, Zenda S, et al. Analysis of dose-volume histogram parameters for radiation pneumonitis after definitive concurrent chemoradiotherapy for esophageal cancer [J]. Radiother Oncol. 2010;95(2):240\u0026ndash;4.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eXu C, Xi M, Moreno A, et al. Definitive Chemoradiation Therapy for Esophageal Cancer in the Elderly: Clinical Outcomes for Patients Exceeding 80 Years Old [J]. Int J Radiat Oncol Biol Phys. 2017;98(4):811\u0026ndash;9.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTanabe S, Myojin M, Shimizu S, et al. Dose-volume analysis for respiratory toxicity in intrathoracic esophageal cancer patients treated with definitive chemoradiotherapy using extended fields [J]. J Radiat Res. 2013;54(6):1085\u0026ndash;94.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhao Y, Chen L, Zhang S, et al. Predictive factors for acute radiation pneumonitis in postoperative intensity modulated radiation therapy and volumetric modulated arc therapy of esophageal cancer [J]. Thorac Cancer. 2015;6(1):49\u0026ndash;57.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLan K, Zhu J, Zhang J, et al. Propensity score-based comparison of survival and radiation pneumonitis after definitive chemoradiation for esophageal cancer: Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy [J]. Radiother Oncol. 2020;149:228\u0026ndash;35.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eInoo H, Sakanaka K, Fujii K, et al. Association of volumetric-modulated arc therapy with radiation pneumonitis in thoracic esophageal cancer [J]. J Radiat Res. 2022;63(4):646\u0026ndash;56.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBradley J, Movsas B. Radiation pneumonitis and esophagitis in thoracic irradiation [J]. Cancer Treat Res. 2006;128:43\u0026ndash;64.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBernchou U, Schytte T, Bertelsen A, et al. Time evolution of regional CT density changes in normal lung after IMRT for NSCLC [J]. Radiother Oncol. 2013;109(1):89\u0026ndash;94.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHuang BT, Lin PX, Wang Y et al. Developing a Prediction Model for Radiation Pneumonitis in Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy Combined With Clinical, Dosimetric Factors, and Laboratory Biomarkers [J]. Clin Lung Cancer, 2023, 24(8): e323-e31 e2.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAbratt RP, Morgan GW, Silvestri G, et al. Pulmonary complications of radiation therapy [J]. Clin Chest Med. 2004;25(1):167\u0026ndash;77.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFine A, Goldstein RH. The effect of transforming growth factor-beta on cell proliferation and collagen formation by lung fibroblasts [J]. J Biol Chem. 1987;262(8):3897\u0026ndash;902.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGuo L, Ding G, Xu W, et al. Prognostic biological factors of radiation pneumonitis after stereotactic body radiation therapy combined with pulmonary perfusion imaging [J]. Exp Ther Med. 2019;17(1):244\u0026ndash;50.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHanania AN, Mainwaring W, Ghebre YT, et al. Radiation-Induced Lung Injury: Assess Manage [J] Chest. 2019;156(1):150\u0026ndash;62.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDang J, Li G, Zang S, et al. Risk and predictors for early radiation pneumonitis in patients with stage III non-small cell lung cancer treated with concurrent or sequential chemoradiotherapy [J]. Radiat Oncol. 2014;9:172.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRen C, Ji T, Liu T, et al. The risk and predictors for severe radiation pneumonitis in lung cancer patients treated with thoracic reirradiation [J]. Radiat Oncol. 2018;13(1):69.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePalma DA, Senan S, Tsujino K, et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis [J]. Int J Radiat Oncol Biol Phys. 2013;85(2):444\u0026ndash;50.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWatanabe S, Ogino I, Shigenaga D, et al. Relationship Between Radiation Pneumonitis Following Definitive Radiotherapy for Non-small Cell Lung Cancer and Isodose Line [J]. Vivo. 2021;35(6):3441\u0026ndash;8.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTsujino K, Hashimoto T, Shimada T, et al. Combined analysis of V20, VS5, pulmonary fibrosis score on baseline computed tomography, and patient age improves prediction of severe radiation pneumonitis after concurrent chemoradiotherapy for locally advanced non-small-cell lung cancer [J]. J Thorac Oncol. 2014;9(7):983\u0026ndash;90.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhang XJ, Sun JG, Sun J, et al. Prediction of radiation pneumonitis in lung cancer patients: a systematic review [J]. J Cancer Res Clin Oncol. 2012;138(12):2103\u0026ndash;16.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePinnix CC, Smith GL, Milgrom S, et al. Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma [J]. Int J Radiat Oncol Biol Phys. 2015;92(1):175\u0026ndash;82.\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"},{"header":"Tables","content":" \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eBaseline demographic and clinical characteristics of unresectable locally advanced EC patients treated with RT in the full analysis set.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"9\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c8\" colnum=\"8\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c9\" colnum=\"9\"\u003e\u003c/div\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eBaseline characteristics\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eBaseline characteristics\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003eSum\u003c/p\u003e \u003cp\u003e(n\u0026thinsp;=\u0026thinsp;92)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003eRP\u0026thinsp;\u0026ge;\u0026thinsp;grade 2\u003c/p\u003e \u003cp\u003e(n\u0026thinsp;=\u0026thinsp;16, 17.39%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c8\" namest=\"c7\"\u003e \u003cp\u003eNon-RP\u0026thinsp;\u0026lt;\u0026thinsp;grade 2\u003c/p\u003e \u003cp\u003e(n\u0026thinsp;=\u0026thinsp;76, 82.61%)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003ep-\u003c/p\u003e \u003cp\u003evalue\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eAge\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026le;\u0026thinsp;65\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e22\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e23.91\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e37.50\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e16\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e21.05\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e0.1610\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026gt;65\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e70\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e76.09\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e62.50\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e60\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e78.95\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eRP\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003enon-RP\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e76\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e82.61\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e76\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e100.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eRP\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e16\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e17.39\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e16\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e100.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"3\" rowspan=\"4\"\u003e \u003cp\u003eRP Grade\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0\u0026ndash;1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e76\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e82.61\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e76\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e100.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e16\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e17.39\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e16\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e100.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eGender\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eFemale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e33\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e35.87\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e43.75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e26\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e34.21\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e0.5696\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e59\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e64.13\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e56.25\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e50\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e65.79\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eSmoke\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003enon-smoker\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e74\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e80.43\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e14\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e87.50\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e60\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e78.95\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e0.4332\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003esmoker\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e18\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e19.57\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e12.50\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e16\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e21.05\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003ePathology\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003esquamous carcinoma\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e88\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e95.65\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e15\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e93.75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e73\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e96.05\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e0.5408\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eother\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4.35\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e6.25\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e3.95\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"4\" rowspan=\"5\"\u003e \u003cp\u003eLocation\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ecervical EC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e3.26\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e3.95\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\" morerows=\"4\" rowspan=\"5\"\u003e \u003cp\u003e0.9704\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eUpper thoracic EC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e10.87\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e12.50\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e10.53\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMiddle thoracic EC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e53\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e57.61\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e56.25\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e44\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e57.89\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eLower thoracic EC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e24\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e26.09\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e31.25\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e19\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e25.00\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eOther\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2.17\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e2.63\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"3\" rowspan=\"4\"\u003e \u003cp\u003ecTNM\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eI\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e8.70\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e6.25\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e9.21\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\" morerows=\"3\" rowspan=\"4\"\u003e \u003cp\u003e\u0026gt;\u0026thinsp;0.99\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eII\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e15\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e16.30\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e18.75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e12\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e15.79\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eIII\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e51\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e55.43\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e56.25\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e42\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e55.26\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eIV\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e18\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e19.57\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e18.75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e15\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e19.74\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"3\" rowspan=\"4\"\u003e \u003cp\u003eT stage\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e8.70\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e6.25\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e9.21\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\" morerows=\"3\" rowspan=\"4\"\u003e \u003cp\u003e0.5854\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e14\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e15.22\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e6.25\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e13\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e17.11\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e15\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e16.30\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e25.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e14.47\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e55\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e59.78\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e62.50\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e45\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e59.21\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"3\" rowspan=\"4\"\u003e \u003cp\u003eN stage\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e28\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e30.43\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e25.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e24\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e31.58\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\" morerows=\"3\" rowspan=\"4\"\u003e \u003cp\u003e0.2503\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e45\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e48.91\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e43.75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e38\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e50.00\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e18\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e19.57\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e25.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e14\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e18.42\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.09\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e6.25\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eM stage\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e77\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e83.70\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e15\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e93.75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e62\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e81.58\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e0.4551\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e15\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e16.30\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e6.25\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e14\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e18.42\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eBaseline demographic and clinical characteristics of unresectable locally advanced EC patients treated with immunotherapy and RT in the full analysis set.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"9\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c8\" colnum=\"8\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c9\" colnum=\"9\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eBaseline characteristics\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003eSum\u003c/p\u003e \u003cp\u003e(n\u0026thinsp;=\u0026thinsp;84)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003eRP\u0026thinsp;\u0026ge;\u0026thinsp;grade 2\u003c/p\u003e \u003cp\u003e(n\u0026thinsp;=\u0026thinsp;26, 30.95%)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c8\" namest=\"c7\"\u003e \u003cp\u003eNon-RP\u0026thinsp;\u0026lt;\u0026thinsp;grade 2\u003c/p\u003e \u003cp\u003e(n\u0026thinsp;=\u0026thinsp;58, 69.05% )\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c9\"\u003e \u003cp\u003eP-\u003c/p\u003e \u003cp\u003evalue\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eAge\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026le;\u0026thinsp;65\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e18\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e21.43\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e42.31\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e12.07\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e\u003cb\u003e0.002\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e\u0026gt;65\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e66\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e78.57\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e15\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e57.69\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e51\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e87.93\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eRP\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003enon-RP\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e58\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e69.05\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e58\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e100.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eRP\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e26\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e30.95\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e26\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e100.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"3\" rowspan=\"4\"\u003e \u003cp\u003eRP Grade\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0\u0026ndash;1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e58\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e69.05\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e58\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e100.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e23\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e27.06\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e23\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e88.46\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1.18\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e3.85\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2.35\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e7.69\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eGender\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eFemale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e27\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e32.14\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e26.92\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e20\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e34.48\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e0.4928\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMale\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e57\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e67.86\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e19\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e73.08\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e38\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e65.52\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eSmoke\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003enon-smoker\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e68\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e80.95\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e18\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e69.23\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e50\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e86.21\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e0.0670\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003esmoker\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e16\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e19.05\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e30.77\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e13.79\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003ePathology\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003esquamous cell carcinoma\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e82\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e97.62\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e26\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e100.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e56\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e96.55\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eother\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2.35\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e3.57\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"4\" rowspan=\"5\"\u003e \u003cp\u003eLocation\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCervical EC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2.38\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e3.85\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e1.72\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\" morerows=\"4\" rowspan=\"5\"\u003e \u003cp\u003e0.9669\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eUpper thoracic EC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e13.10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e11.54\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e13.79\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMiddle thoracic EC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e46\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e54.76\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e15\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e57.69\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e31\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e53.45\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eLower thoracic EC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e16\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e19.05\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e19.23\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e18.97\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eOther\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e10.71\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e7.69\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e12.07\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"5\" rowspan=\"6\"\u003e \u003cp\u003eImmunotherapy drugs\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eatezolizumab\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4.76\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e7.69\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e3.45\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\" morerows=\"5\" rowspan=\"6\"\u003e \u003cp\u003e0.1500\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ecamrelizumab\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e28\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e33.33\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e34.62\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e19\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e32.76\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003epembrolizumab\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e10.71\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e7.69\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e12.07\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003etoripalimab\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4.76\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e3.85\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e5.17\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003etislelizumab\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e29\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e34.52\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e12\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e46.15\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e17\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e29.31\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003esintilimab\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e11.91\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e17.24\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eImmunotherapy type\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePD-1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e80\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e95.24\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e24\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e92.31\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e56\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e96.55\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e0.5842\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePD-L1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4.76\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e7.69\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e3.45\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"2\" rowspan=\"3\"\u003e \u003cp\u003eSequence of RT and immunotherapy\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eConcurrent\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e43\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e50.59\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e17\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e65.38\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e26\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e44.83\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\" morerows=\"2\" rowspan=\"3\"\u003e \u003cp\u003e0.1506\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eRT first\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e32\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e37.65\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e23.08\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e26\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e44.83\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eimmunotherapy first\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e11.76\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e11.54\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e10.34\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"3\" rowspan=\"4\"\u003e \u003cp\u003ecTNM\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eI\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2.38\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e3.85\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e1.72\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\" morerows=\"3\" rowspan=\"4\"\u003e \u003cp\u003e0.5167\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eII\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e11.91\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e7.69\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e13.80\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eIII\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e25\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e29.76\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e38.46\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e15\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e25.86\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eIV\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e47\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e55.95\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e13\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e50.00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e34\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e58.62\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"3\" rowspan=\"4\"\u003e \u003cp\u003eT stage\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4.76\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e7.69\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e3.45\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\" morerows=\"3\" rowspan=\"4\"\u003e \u003cp\u003e0.2894\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e14\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e16.67\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e11.54\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e18.97\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e26\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e30.95\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e42.31\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e15\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e25.86\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e40\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e47.62\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e38.46\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e30\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e51.72\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"2\" rowspan=\"3\"\u003e \u003cp\u003eN stage\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e19\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e22.62\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e26.92\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e12\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e20.69\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\" morerows=\"2\" rowspan=\"3\"\u003e \u003cp\u003e0.5168\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e37\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e44.05\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e34.62\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e28\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e48.28\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e28\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e33.33\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e38.46\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e18\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e31.03\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eM stage\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e69\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e82.14\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e22\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e84.62\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e47\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e81.03\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e0.7683\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e15\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e17.86\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e15.38\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e18.97\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"2\" rowspan=\"3\"\u003e \u003cp\u003eIrradiation segmentation dose\u003c/p\u003e \u003cp\u003e(Gy)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e40\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e47.62\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e15\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e57.69\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e25\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e43.10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\" morerows=\"2\" rowspan=\"3\"\u003e \u003cp\u003e0.4415\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2.0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e19\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e22.62\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e15.38\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e15\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e25.86\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1.8\u0026thinsp;+\u0026thinsp;2.0\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e25\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e29.76\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e26.92\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e18\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e31.03\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"9\" nameend=\"c9\" namest=\"c1\"\u003e \u003cp\u003eData are n (100%).\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e\u003cstrong\u003eTable 3A Logistic regression analysis of clinical parameters associated with RP among patients treated with RT.\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" width=\"99%\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"44.89795918367347%\" rowspan=\"2\"\u003e\n \u003cp\u003e\u003cstrong\u003eClinical parameters\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.26530612244898%\" rowspan=\"2\"\u003e\n \u003cp\u003e\u003cstrong\u003ep-value\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.26530612244898%\" rowspan=\"2\"\u003e\n \u003cp\u003e\u003cstrong\u003eOR\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.571428571428573%\" colspan=\"2\"\u003e\n \u003cp\u003e\u003cstrong\u003e95% CI\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"51.851851851851855%\" style=\"width: 25.8675%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eUpper\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"48.148148148148145%\" style=\"width: 6.4669%;\"\u003e\n \u003cp\u003e\u003cstrong\u003eDown\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"45.36082474226804%\"\u003e\n \u003cp\u003eAge\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.402061855670103%\" valign=\"top\"\u003e\n \u003cp\u003e0.252\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.402061855670103%\" valign=\"top\"\u003e\n \u003cp\u003e0.958\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.43298969072165%\" valign=\"top\" style=\"width: 25.8675%;\"\u003e\n \u003cp\u003e0.89\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.402061855670103%\" valign=\"top\" style=\"width: 6.4669%;\"\u003e\n \u003cp\u003e1.031\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"45.36082474226804%\"\u003e\n \u003cp\u003eTD\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.402061855670103%\" valign=\"top\"\u003e\n \u003cp\u003e0.284\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.402061855670103%\" valign=\"top\"\u003e\n \u003cp\u003e1.098\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.43298969072165%\" valign=\"top\" style=\"width: 25.8675%;\"\u003e\n \u003cp\u003e0.925\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.402061855670103%\" valign=\"top\" style=\"width: 6.4669%;\"\u003e\n \u003cp\u003e1.303\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"45.36082474226804%\"\u003e\n \u003cp\u003ePTV\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.402061855670103%\" valign=\"top\"\u003e\n \u003cp\u003e0.245\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.402061855670103%\" valign=\"top\"\u003e\n \u003cp\u003e1.003\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.43298969072165%\" valign=\"top\" style=\"width: 25.8675%;\"\u003e\n \u003cp\u003e0.998\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.402061855670103%\" valign=\"top\" style=\"width: 6.4669%;\"\u003e\n \u003cp\u003e1.007\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"45.36082474226804%\"\u003e\n \u003cp\u003eMLD\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.402061855670103%\" valign=\"top\"\u003e\n \u003cp\u003e0.624\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.402061855670103%\" valign=\"top\"\u003e\n \u003cp\u003e1.007\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.43298969072165%\" valign=\"top\" style=\"width: 25.8675%;\"\u003e\n \u003cp\u003e0.98\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.402061855670103%\" valign=\"top\" style=\"width: 6.4669%;\"\u003e\n \u003cp\u003e1.034\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"45.36082474226804%\"\u003e\n \u003cp\u003eV5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.402061855670103%\" valign=\"top\"\u003e\n \u003cp\u003e0.568\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.402061855670103%\" valign=\"top\"\u003e\n \u003cp\u003e0.915\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.43298969072165%\" valign=\"top\" style=\"width: 25.8675%;\"\u003e\n \u003cp\u003e0.674\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.402061855670103%\" valign=\"top\" style=\"width: 6.4669%;\"\u003e\n \u003cp\u003e1.241\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"45.36082474226804%\"\u003e\n \u003cp\u003eV10\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.402061855670103%\" valign=\"top\"\u003e\n \u003cp\u003e0.349\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.402061855670103%\" valign=\"top\"\u003e\n \u003cp\u003e1.267\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.43298969072165%\" valign=\"top\" style=\"width: 25.8675%;\"\u003e\n \u003cp\u003e0.772\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.402061855670103%\" valign=\"top\" style=\"width: 6.4669%;\"\u003e\n \u003cp\u003e2.08\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"45.36082474226804%\"\u003e\n \u003cp\u003eV15\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.402061855670103%\" valign=\"top\"\u003e\n \u003cp\u003e0.089\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.402061855670103%\" valign=\"top\"\u003e\n \u003cp\u003e0.527\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.43298969072165%\" valign=\"top\" style=\"width: 25.8675%;\"\u003e\n \u003cp\u003e0.252\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.402061855670103%\" valign=\"top\" style=\"width: 6.4669%;\"\u003e\n \u003cp\u003e1.101\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"45.36082474226804%\"\u003e\n \u003cp\u003eV20\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.402061855670103%\" valign=\"top\"\u003e\n \u003cp\u003e0.098\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.402061855670103%\" valign=\"top\"\u003e\n \u003cp\u003e2.075\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.43298969072165%\" valign=\"top\" style=\"width: 25.8675%;\"\u003e\n \u003cp\u003e0.874\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.402061855670103%\" valign=\"top\" style=\"width: 6.4669%;\"\u003e\n \u003cp\u003e4.927\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"45.36082474226804%\"\u003e\n \u003cp\u003eV25\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.402061855670103%\" valign=\"top\"\u003e\n \u003cp\u003e0.459\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.402061855670103%\" valign=\"top\"\u003e\n \u003cp\u003e0.659\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.43298969072165%\" valign=\"top\" style=\"width: 25.8675%;\"\u003e\n \u003cp\u003e0.219\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.402061855670103%\" valign=\"top\" style=\"width: 6.4669%;\"\u003e\n \u003cp\u003e1.987\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"45.36082474226804%\"\u003e\n \u003cp\u003eV30\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.402061855670103%\" valign=\"top\"\u003e\n \u003cp\u003e0.934\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.402061855670103%\" valign=\"top\"\u003e\n \u003cp\u003e0.962\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.43298969072165%\" valign=\"top\" style=\"width: 25.8675%;\"\u003e\n \u003cp\u003e0.384\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"13.402061855670103%\" valign=\"top\" style=\"width: 6.4669%;\"\u003e\n \u003cp\u003e2.408\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cbr\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 3B Logistic regression analysis of clinical parameters associated with RP among patients treated with RT and immunotherapy.\u003c/strong\u003e\u003c/p\u003e\n\u003ctable style=\"float: left;border: none;width:99.96%;border-collapse:collapse;margin-left:6.75pt;margin-right:6.75pt;\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd rowspan=\"2\" style=\"width:44.66%;border-top:solid #305BC7 2.25pt;border-left:none;border-bottom:solid #305BC7 1.0pt;border-right:none;background:#B5C7EA;padding:0in 5.4pt 0in 5.4pt;height:17.55pt;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cstrong\u003e\u003cspan style='font-family:\"Times New Roman Bold\";color:black;'\u003eClinical parameters\u003c/span\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width:13.6%;border-top:solid #305BC7 2.25pt;border-left:none;border-bottom:solid #305BC7 1.0pt;border-right:none;background:#B5C7EA;padding:0in 5.4pt 0in 5.4pt;height:17.55pt;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cstrong\u003e\u003cspan style='font-family:\"Times New Roman Bold\";color:black;'\u003ep-value\u003c/span\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd rowspan=\"2\" style=\"width:13.6%;border-top:solid #305BC7 2.25pt;border-left:none;border-bottom:solid #305BC7 1.0pt;border-right:none;background:#B5C7EA;padding:0in 5.4pt 0in 5.4pt;height:17.55pt;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cstrong\u003e\u003cspan style='font-family:\"Times New Roman Bold\";color:black;'\u003eOR\u003c/span\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd colspan=\"2\" style=\"width:28.12%;border-top:solid #305BC7 2.25pt;border-left:none;border-bottom:solid #4874CB 1.0pt;border-right:none;background:#B5C7EA;padding:0in 5.4pt 0in 5.4pt;height:17.55pt;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cstrong\u003e\u003cspan style='font-family:\"Times New Roman Bold\";color:black;'\u003e95% CI\u003c/span\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:14.48%;border:none;border-bottom:solid #305BC7 1.0pt;background:#B5C7EA;padding:0in 5.4pt 0in 5.4pt;height:17.55pt;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cstrong\u003e\u003cspan style='font-family:\"Times New Roman Bold\";color:black;'\u003eUpper\u003c/span\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:13.64%;border:none;border-bottom:solid #305BC7 1.0pt;background:#B5C7EA;padding:0in 5.4pt 0in 5.4pt;height:17.55pt;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cstrong\u003e\u003cspan style='font-family:\"Times New Roman Bold\";color:black;'\u003eDown\u003c/span\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:44.66%;border:none;border-right:solid #4874CB 1.0pt;background:white;padding:0in 5.4pt 0in 5.4pt;height:17.55pt;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003eAge\u0026nbsp;\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:13.6%;border:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:17.55pt;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:red;'\u003e0.010\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:13.6%;border:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:17.55pt;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e0.976\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 61.7pt;border: none;background: white;padding: 0in 5.4pt;height: 17.55pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e0.892\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 58.2pt;border: none;background: white;padding: 0in 5.4pt;height: 17.55pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e0.815\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:44.66%;border:none;border-right:solid #4874CB 1.0pt;background:#EDF1FA;padding:0in 5.4pt 0in 5.4pt;height:17.55pt;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003eTotal irradiation dose\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:13.6%;border:none;background:#EDF1FA;padding:0in 5.4pt 0in 5.4pt;height:17.55pt;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:red;'\u003e0.036\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:13.6%;background:#EDF1FA;padding:0in 5.4pt 0in 5.4pt;height:17.55pt;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e1.603\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 61.7pt;background: rgb(237, 241, 250);padding: 0in 5.4pt;height: 17.55pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e1.277\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 58.2pt;background: rgb(237, 241, 250);padding: 0in 5.4pt;height: 17.55pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e1.016\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:44.66%;border:none;border-right:solid #4874CB 1.0pt;background:white;padding:0in 5.4pt 0in 5.4pt;height:17.55pt;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003eirradiation segmentation frequency\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:13.6%;border:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:17.55pt;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:red;'\u003e0.009\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:13.6%;background:white;padding:0in 5.4pt 0in 5.4pt;height:17.55pt;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e0.903\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 61.7pt;background: white;padding: 0in 5.4pt;height: 17.55pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e0.665\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 58.2pt;background: white;padding: 0in 5.4pt;height: 17.55pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e0.49\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:44.66%;border:none;border-right:solid #4874CB 1.0pt;background:#EDF1FA;padding:0in 5.4pt 0in 5.4pt;height:17.55pt;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003eGTVp\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:13.6%;border:none;background:#EDF1FA;padding:0in 5.4pt 0in 5.4pt;height:17.55pt;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e0.355\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57.95pt;background: rgb(237, 241, 250);padding: 0in 5.4pt;height: 17.55pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e1.014\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 61.7pt;background: rgb(237, 241, 250);padding: 0in 5.4pt;height: 17.55pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e0.988\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 58.2pt;background: rgb(237, 241, 250);padding: 0in 5.4pt;height: 17.55pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e0.963\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:44.66%;border:none;border-right:solid #4874CB 1.0pt;background:white;padding:0in 5.4pt 0in 5.4pt;height:17.55pt;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003ePTV\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:13.6%;border:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:17.55pt;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e0.205\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57.95pt;background: white;padding: 0in 5.4pt;height: 17.55pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e1.009\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 61.7pt;background: white;padding: 0in 5.4pt;height: 17.55pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e1.003\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 58.2pt;background: white;padding: 0in 5.4pt;height: 17.55pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e0.998\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:44.66%;border:none;border-right:solid #4874CB 1.0pt;background:#EDF1FA;padding:0in 5.4pt 0in 5.4pt;height:17.55pt;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003eMLD\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:13.6%;border:none;background:#EDF1FA;padding:0in 5.4pt 0in 5.4pt;height:17.55pt;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e0.752\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57.95pt;background: rgb(237, 241, 250);padding: 0in 5.4pt;height: 17.55pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e1.012\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 61.7pt;background: rgb(237, 241, 250);padding: 0in 5.4pt;height: 17.55pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e1.002\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 58.2pt;background: rgb(237, 241, 250);padding: 0in 5.4pt;height: 17.55pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e0.991\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:44.66%;border:none;border-right:solid #4874CB 1.0pt;background:white;padding:0in 5.4pt 0in 5.4pt;height:17.55pt;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003eV5\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:13.6%;border:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:17.55pt;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e0.562\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57.95pt;background: white;padding: 0in 5.4pt;height: 17.55pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e1.04\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 61.7pt;background: white;padding: 0in 5.4pt;height: 17.55pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e1.009\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 58.2pt;background: white;padding: 0in 5.4pt;height: 17.55pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e0.979\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:44.66%;border:none;border-right:solid #4874CB 1.0pt;background:#EDF1FA;padding:0in 5.4pt 0in 5.4pt;height:17.55pt;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003eV10\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:13.6%;border:none;background:#EDF1FA;padding:0in 5.4pt 0in 5.4pt;height:17.55pt;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e0.519\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57.95pt;background: rgb(237, 241, 250);padding: 0in 5.4pt;height: 17.55pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e1.503\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 61.7pt;background: rgb(237, 241, 250);padding: 0in 5.4pt;height: 17.55pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e1.106\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 58.2pt;background: rgb(237, 241, 250);padding: 0in 5.4pt;height: 17.55pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e0.814\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:44.66%;border:none;border-right:solid #4874CB 1.0pt;background:white;padding:0in 5.4pt 0in 5.4pt;height:17.55pt;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003eV15\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:13.6%;border:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:17.55pt;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:red;'\u003e0.043\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57.95pt;background: white;padding: 0in 5.4pt;height: 17.55pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e0.98\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 61.7pt;background: white;padding: 0in 5.4pt;height: 17.55pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e0.507\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 58.2pt;background: white;padding: 0in 5.4pt;height: 17.55pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e0.262\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:44.66%;border:none;border-right:solid #4874CB 1.0pt;background:#EDF1FA;padding:0in 5.4pt 0in 5.4pt;height:17.55pt;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003eV20\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:13.6%;border:none;background:#EDF1FA;padding:0in 5.4pt 0in 5.4pt;height:17.55pt;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e0.155\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57.95pt;background: rgb(237, 241, 250);padding: 0in 5.4pt;height: 17.55pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e5.358\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 61.7pt;background: rgb(237, 241, 250);padding: 0in 5.4pt;height: 17.55pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e2.026\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 58.2pt;background: rgb(237, 241, 250);padding: 0in 5.4pt;height: 17.55pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e0.766\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:44.66%;border:none;border-right:solid #4874CB 1.0pt;background:white;padding:0in 5.4pt 0in 5.4pt;height:17.55pt;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003eV25\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:13.6%;border:none;background:white;padding:0in 5.4pt 0in 5.4pt;height:17.55pt;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e0.651\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57.95pt;background: white;padding: 0in 5.4pt;height: 17.55pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e2.164\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 61.7pt;background: white;padding: 0in 5.4pt;height: 17.55pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e0.793\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 58.2pt;background: white;padding: 0in 5.4pt;height: 17.55pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e0.291\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width:44.66%;border-top:none;border-left:none;border-bottom:solid #305BC7 2.25pt;border-right:solid #4874CB 1.0pt;background:#EDF1FA;padding:0in 5.4pt 0in 5.4pt;height:17.55pt;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003eV30\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width:13.6%;border:none;border-bottom:solid #305BC7 2.25pt;background:#EDF1FA;padding:0in 5.4pt 0in 5.4pt;height:17.55pt;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e0.974\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 57.95pt;border-top: none;border-right: none;border-left: none;border-image: initial;border-bottom: 2.25pt solid rgb(48, 91, 199);background: rgb(237, 241, 250);padding: 0in 5.4pt;height: 17.55pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e1.607\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 61.7pt;border-top: none;border-right: none;border-left: none;border-image: initial;border-bottom: 2.25pt solid rgb(48, 91, 199);background: rgb(237, 241, 250);padding: 0in 5.4pt;height: 17.55pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e0.992\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 58.2pt;border-top: none;border-right: none;border-left: none;border-image: initial;border-bottom: 2.25pt solid rgb(48, 91, 199);background: rgb(237, 241, 250);padding: 0in 5.4pt;height: 17.55pt;vertical-align: top;\"\u003e\n \u003cp style='margin:0in;text-align:center;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-family:\"Times New Roman Regular\";color:black;'\u003e0.613\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd colspan=\"5\" style=\"width:100.0%;border:none;padding:0in 5.4pt 0in 5.4pt;height:17.55pt;\"\u003e\n \u003cp style='margin:0in;text-align:justify;font-size:14px;font-family:\"Calibri\",sans-serif;vertical-align:middle;'\u003e\u003cspan style='font-size:11px;font-family:\"Times New Roman\",serif;'\u003eAbbreviations: OR: Odds ratio; CI: Confidence interval; GTVp: gross tumor volume (the primary esophageal mass volume based on imaging studies); PTV: planning target volume; MLD: mean lung dose; Vx: volume of lung receiving \u0026ge; x Gy.\u003c/span\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab4\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 4\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eA Clinical parameters selected to construct RP risk model by multivariate Cox regression analysis among patients treated with RT.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"11\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c8\" colnum=\"8\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c9\" colnum=\"9\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c10\" colnum=\"10\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c11\" colnum=\"11\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eClinical parameters\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" morerows=\"1\" nameend=\"c3\" namest=\"c2\" rowspan=\"2\"\u003e \u003cp\u003eCoef\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" morerows=\"1\" nameend=\"c5\" namest=\"c4\" rowspan=\"2\"\u003e \u003cp\u003eHR\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"4\" nameend=\"c9\" namest=\"c6\"\u003e \u003cp\u003e95% CI\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" morerows=\"1\" nameend=\"c11\" namest=\"c10\" rowspan=\"2\"\u003e \u003cp\u003eP-value\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003ctr\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003eHR.95L\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c9\" namest=\"c8\"\u003e \u003cp\u003eHR.95H\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eAge\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e-0.0594\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e0.9423\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.8968\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c9\" namest=\"c8\"\u003e \u003cp\u003e0.9902\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c11\" namest=\"c10\"\u003e \u003cp\u003e0.0188\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e0.6899\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e1.9935\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.9852\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c9\" namest=\"c8\"\u003e \u003cp\u003e4.0338\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c11\" namest=\"c10\"\u003e \u003cp\u003e0.0551\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eM\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e-1.8524\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e0.1569\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e0.0194\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c9\" namest=\"c8\"\u003e \u003cp\u003e1.2713\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c11\" namest=\"c10\"\u003e \u003cp\u003e0.0827\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eV20\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e0.1205\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e1.1281\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e1.0175\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c9\" namest=\"c8\"\u003e \u003cp\u003e1.2506\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c11\" namest=\"c10\"\u003e \u003cp\u003e0.0220\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"11\" nameend=\"c11\" namest=\"c1\"\u003e \u003cp\u003eAbbreviations: HR: Hazard ratio; CI: Confidence interval; Coef: coefficient value.\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"11\" nameend=\"c11\" namest=\"c1\"\u003e \u003cp\u003eTable\u0026nbsp;\u003cspan refid=\"Tab4\" class=\"InternalRef\"\u003e4\u003c/span\u003eB \u003cb\u003eClinical parameters selected to construct RP risk model by multivariate Cox regression analysis among patients treated with RT and immunotherapy.\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" morerows=\"1\" nameend=\"c2\" namest=\"c1\" rowspan=\"2\"\u003e \u003cp\u003e\u003cb\u003eClinical parameters\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" morerows=\"1\" nameend=\"c4\" namest=\"c3\" rowspan=\"2\"\u003e \u003cp\u003e\u003cb\u003eCoef\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" morerows=\"1\" nameend=\"c6\" namest=\"c5\" rowspan=\"2\"\u003e \u003cp\u003e\u003cb\u003eHR\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"4\" nameend=\"c10\" namest=\"c7\"\u003e \u003cp\u003e\u003cb\u003e95% CI\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e\u003cb\u003eP-value\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c8\" namest=\"c7\"\u003e \u003cp\u003e\u003cb\u003eHR.95L\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c10\" namest=\"c9\"\u003e \u003cp\u003e\u003cb\u003eHR.95H\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eAge\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e-0.0555\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003e0.9460\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c8\" namest=\"c7\"\u003e \u003cp\u003e0.8996\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c10\" namest=\"c9\"\u003e \u003cp\u003e0.9949\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.0308\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eTotal irradiation dose\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e0.1292\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003e1.1379\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c8\" namest=\"c7\"\u003e \u003cp\u003e0.9834\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c10\" namest=\"c9\"\u003e \u003cp\u003e1.3166\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.0827\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eIrradiation segmentation Frequency\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e-0.2191\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003e0.8033\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c8\" namest=\"c7\"\u003e \u003cp\u003e0.6651\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c10\" namest=\"c9\"\u003e \u003cp\u003e0.9702\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.0229\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eV15\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e-0.2134\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003e0.8078\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c8\" namest=\"c7\"\u003e \u003cp\u003e0.6562\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c10\" namest=\"c9\"\u003e \u003cp\u003e0.9945\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.0443\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eV20\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003e0.2214\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c6\" namest=\"c5\"\u003e \u003cp\u003e1.2478\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c8\" namest=\"c7\"\u003e \u003cp\u003e0.9712\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c10\" namest=\"c9\"\u003e \u003cp\u003e1.6034\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c11\"\u003e \u003cp\u003e0.0834\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"11\" nameend=\"c11\" namest=\"c1\"\u003e \u003cp\u003eAbbreviations: HR: Hazard ratio; CI: Confidence interval; Coef: coefficient value.\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e "}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"esophageal cancer, predictive model, radiation, pneumonitis, immunotherapy","lastPublishedDoi":"10.21203/rs.3.rs-4345357/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4345357/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eBackground\u003c/h2\u003e \u003cp\u003eRadiation therapy (RT) is an essential treatment for esophageal cancer with radiation induced pneumonitis (RP) as a possible adverse event. With the emergence of immunotherapy for patients with esophageal cancer (EC), whether in combination with RT or alone it increases RP incidence, which leads to the need of reevaluating the RP risk predication paraments.\u003c/p\u003e\u003ch2\u003eMethods\u003c/h2\u003e \u003cp\u003eClinical and physical parameters were collected from patients with clinicopathologically confirmed unresectable locally advanced EC from 1/2020 and 7/2023. The endpoint was Grade\u0026thinsp;\u0026ge;\u0026thinsp;2 RP occurrence within 6 months after radiotherapy. The χ\u003csup\u003e2\u003c/sup\u003e test and Logistic regression analysis were used to analyze the relationship of categorical and continuous variables with RP occurrence respectively. Multivariate Cox analysis was used to construct a RP risk model by R software, the accuracy of which was further evaluated by ROC and risk curves.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e \u003cp\u003eAfter strict screening, 92 patients receiving RT alone and 84 patients receiving RT\u0026thinsp;+\u0026thinsp;Immunotherapy were eligible for inclusion in this study. The incidence of grade\u0026thinsp;\u0026ge;\u0026thinsp;2 RP in patients with EC who received RT and immunotherapy was 30.95%, which is higher compared to those who received RT alone (17.39%). Several factors were included for the construction of RP Risk Model by multivariate Cox regression in group RT and RT-I seperatly. Four factors were used for RP prediction risk model in patients who received the RT alone, and five factors were used for RP prediction risk model in patients who received the RT\u0026thinsp;+\u0026thinsp;Immunotherapy. The ROC curve indicated the satisfactory accuracy with AUC value was 0.734 and 0.805 in group RT and RT-I respectively. Risk curves confirmed favorable accuracy that the higher risk score, the higher RP risk, the lower interval times when RP happens after RT.\u003c/p\u003e\u003ch2\u003eConclusions\u003c/h2\u003e \u003cp\u003e(1) The immunotherapy may increase the risk of RP. (2) We screened out five indicators (age, total irradiation dose, irradiation segmentation frequency, V15 and V20) for predicting RP incidence in EC patients receiving RT and immunotherapy combination, which provided an important theoretical basis for the RT treatment plan.\u003c/p\u003e","manuscriptTitle":"Predictive risk model for radiation-induced pneumonitis in patients diagnosed with advanced esophageal cancer receiving radiation therapy alone or in combination with immunotherapy: A retrospective study","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-05-09 18:21:48","doi":"10.21203/rs.3.rs-4345357/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"326761d1-0b7e-40c6-93d8-72ffcbac2050","owner":[],"postedDate":"May 9th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2024-07-01T09:12:30+00:00","versionOfRecord":[],"versionCreatedAt":"2024-05-09 18:21:48","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-4345357","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4345357","identity":"rs-4345357","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}